JP2021520405A - 療法におけるp2rx7モジュレーター - Google Patents
療法におけるp2rx7モジュレーター Download PDFInfo
- Publication number
- JP2021520405A JP2021520405A JP2021501093A JP2021501093A JP2021520405A JP 2021520405 A JP2021520405 A JP 2021520405A JP 2021501093 A JP2021501093 A JP 2021501093A JP 2021501093 A JP2021501093 A JP 2021501093A JP 2021520405 A JP2021520405 A JP 2021520405A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- group
- hei
- arh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 title claims description 58
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title claims description 50
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 174
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 103
- 201000011510 cancer Diseases 0.000 claims abstract description 43
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 17
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 7
- -1 2,4-dimethoxyphenyl Chemical group 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 230000030833 cell death Effects 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 238000011374 additional therapy Methods 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000037976 chronic inflammation Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 201000002454 adrenal cortex cancer Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 255
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 79
- XFDLAUDFTNZPNJ-AWEZNQCLSA-N (2S)-1-N-(6-chloropyridin-3-yl)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=CC=C(C=N1)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl XFDLAUDFTNZPNJ-AWEZNQCLSA-N 0.000 description 75
- 241000699670 Mus sp. Species 0.000 description 69
- 238000000034 method Methods 0.000 description 37
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- 238000003786 synthesis reaction Methods 0.000 description 33
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 30
- 239000000460 chlorine Substances 0.000 description 29
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 27
- JZIGGCUPZSGUSI-JTQLQIEISA-N (2S)-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide Chemical compound ClC1=C(C=CC(=C1)Cl)CNC([C@H]1NC(CC1)=O)=O JZIGGCUPZSGUSI-JTQLQIEISA-N 0.000 description 26
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 26
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 26
- 239000000843 powder Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 230000004054 inflammatory process Effects 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 19
- 206010061218 Inflammation Diseases 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 238000000921 elemental analysis Methods 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- 102000003810 Interleukin-18 Human genes 0.000 description 14
- 108090000171 Interleukin-18 Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- 206010009887 colitis Diseases 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 8
- 102000008096 B7-H1 Antigen Human genes 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 102000053195 human P2RX7 Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000037449 immunogenic cell death Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 0 N*NC(N([C@@](CC1)C(NCc(ccc(Cl)c2)c2Cl)=O)C1=O)=O Chemical compound N*NC(N([C@@](CC1)C(NCc(ccc(Cl)c2)c2Cl)=O)C1=O)=O 0.000 description 5
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 229940126027 positive allosteric modulator Drugs 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 description 4
- FGTCROZDHDSNIO-UHFFFAOYSA-N 3-(4-quinolinylmethylamino)-N-[4-(trifluoromethoxy)phenyl]-2-thiophenecarboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)C1=C(NCC=2C3=CC=CC=C3N=CC=2)C=CS1 FGTCROZDHDSNIO-UHFFFAOYSA-N 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- MFUVCHZWGSJKEQ-UHFFFAOYSA-N 3,4-dichlorphenylisocyanate Chemical compound ClC1=CC=C(N=C=O)C=C1Cl MFUVCHZWGSJKEQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 3
- 102000003922 Calcium Channels Human genes 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 208000018458 Colitis-Associated Neoplasms Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000005008 immunosuppressive cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 210000002074 inflammatory monocyte Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000001696 purinergic effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OHCHXCOEPPAEGT-KRWDZBQOSA-N (2S)-1-N,2-N-bis[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)N2[C@@H](CCC2=O)C(=O)NCC2=C(C=C(C=C2)Cl)Cl)C=CC(=C1)Cl OHCHXCOEPPAEGT-KRWDZBQOSA-N 0.000 description 2
- VYNPYNVKCQVBAT-INIZCTEOSA-N (2S)-1-N-(2,4-dichlorophenyl)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NC2=C(C=C(C=C2)Cl)Cl)C=CC(=C1)Cl VYNPYNVKCQVBAT-INIZCTEOSA-N 0.000 description 2
- ZYUNQJKIIKUFMJ-INIZCTEOSA-N (2S)-1-N-(2-bromophenyl)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound BrC1=C(C=CC=C1)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl ZYUNQJKIIKUFMJ-INIZCTEOSA-N 0.000 description 2
- KHNWIDPBIOYMSA-QFIPXVFZSA-N (2S)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxo-1-N-(4-phenylphenyl)pyrrolidine-1,2-dicarboxamide Chemical compound C1(=CC=C(C=C1)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl)C1=CC=CC=C1 KHNWIDPBIOYMSA-QFIPXVFZSA-N 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- VBHCPGFCIQDXGZ-UHFFFAOYSA-N 1-isocyanatoadamantane Chemical compound C1C(C2)CC3CC2CC1(N=C=O)C3 VBHCPGFCIQDXGZ-UHFFFAOYSA-N 0.000 description 2
- QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101150093076 IL18 gene Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FVLFZODZTZXOGM-UHFFFAOYSA-N N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-3-carboxamide Chemical compound ClC1=C(CNC(=O)C2CNC(C2)=O)C=CC(=C1)Cl FVLFZODZTZXOGM-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000003666 Placenta Growth Factor Human genes 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 2
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000008951 colonic inflammation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000031261 interleukin-10 production Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 229950010895 midostaurin Drugs 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005851 tumor immunogenicity Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- BONUCGTWQGIGHJ-QDJPGJPLSA-N (2S)-1-N-(1-adamantyl)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound C12(CC3CC(CC(C1)C3)C2)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl BONUCGTWQGIGHJ-QDJPGJPLSA-N 0.000 description 1
- KEDIDPDUNCKCMO-HAVBXNNZSA-N (2S)-1-N-(1-adamantyl)-2-N-[(2-chlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound C12(CC3CC(CC(C1)C3)C2)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=CC=C1)Cl KEDIDPDUNCKCMO-HAVBXNNZSA-N 0.000 description 1
- CEIKNXHUBLHLLI-INIZCTEOSA-N (2S)-1-N-(2-chlorophenyl)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(NC(=O)N2[C@@H](CCC2=O)C(=O)NCC2=C(Cl)C=C(C=C2)Cl)C=CC=C1 CEIKNXHUBLHLLI-INIZCTEOSA-N 0.000 description 1
- CMSILRPRJYTFLU-INIZCTEOSA-N (2S)-1-N-(3,4-dichlorophenyl)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NC2=CC(=C(C=C2)Cl)Cl)C=CC(=C1)Cl CMSILRPRJYTFLU-INIZCTEOSA-N 0.000 description 1
- GVTYYVRJHQCGGS-KRWDZBQOSA-N (2S)-1-N-(3,4-dichlorophenyl)-2-N-[2-(2,4-dichlorophenyl)ethyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC=1C=C(C=CC=1Cl)NC(=O)N1[C@@H](CCC1=O)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl GVTYYVRJHQCGGS-KRWDZBQOSA-N 0.000 description 1
- RBOCHMAHLIRJSW-INIZCTEOSA-N (2S)-1-N-(4-chlorophenyl)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=CC=C(C=C1)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl RBOCHMAHLIRJSW-INIZCTEOSA-N 0.000 description 1
- WFWXQKJRJWJELE-INIZCTEOSA-N (2S)-1-N-[3,5-bis(trifluoromethyl)phenyl]-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl)(F)F WFWXQKJRJWJELE-INIZCTEOSA-N 0.000 description 1
- ONVYYEFDFRNOMR-AWEZNQCLSA-N (2S)-1-N-butyl-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound C(CCC)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl ONVYYEFDFRNOMR-AWEZNQCLSA-N 0.000 description 1
- KESRVBSQVYODCI-INIZCTEOSA-N (2S)-1-N-cyclohexyl-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound C1CC(NC(=O)N2[C@@H](CCC2=O)C(=O)NCC2=C(C=C(C=C2)Cl)Cl)CCC1 KESRVBSQVYODCI-INIZCTEOSA-N 0.000 description 1
- WWEHREYCSWGAHX-ZDUSSCGKSA-N (2S)-1-N-tert-butyl-2-N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound C(C)(C)(C)NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1=C(C=C(C=C1)Cl)Cl WWEHREYCSWGAHX-ZDUSSCGKSA-N 0.000 description 1
- UZLJGQXVKRVBCY-HNNXBMFYSA-N (2S)-2-N-(2,4-dichlorophenyl)-5-oxo-1-N-phenylpyrrolidine-1,2-dicarboxamide Chemical compound C1=CC=CC=C1NC(=O)N1[C@H](C(=O)NC2=CC=C(C=C2Cl)Cl)CCC1=O UZLJGQXVKRVBCY-HNNXBMFYSA-N 0.000 description 1
- VPIBYSLRYUOBBN-INIZCTEOSA-N (2S)-2-N-(cyclohexylmethyl)-5-oxo-1-N-phenylpyrrolidine-1,2-dicarboxamide Chemical compound C1=CC=CC=C1NC(=O)N1[C@@H](CCC1=O)C(=O)NCC1CCCCC1 VPIBYSLRYUOBBN-INIZCTEOSA-N 0.000 description 1
- YHVMZAQECYFVIK-KRWDZBQOSA-N (2S)-2-N-[(2,4-dichlorophenyl)methyl]-1-N-(2,4-dimethoxyphenyl)-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NC2=C(C=C(C=C2)OC)OC)C=CC(=C1)Cl YHVMZAQECYFVIK-KRWDZBQOSA-N 0.000 description 1
- ZJNGBWHTYREFKL-INIZCTEOSA-N (2S)-2-N-[(2,4-dichlorophenyl)methyl]-1-N-(2-iodophenyl)-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NC2=C(C=CC=C2)I)C=CC(=C1)Cl ZJNGBWHTYREFKL-INIZCTEOSA-N 0.000 description 1
- XDYCFXZFYMYZBM-KRWDZBQOSA-N (2S)-2-N-[(2,4-dichlorophenyl)methyl]-1-N-[(3,4-dichlorophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NCC2=CC(=C(C=C2)Cl)Cl)C=CC(=C1)Cl XDYCFXZFYMYZBM-KRWDZBQOSA-N 0.000 description 1
- ZHLIEDIGONTFNL-INIZCTEOSA-N (2S)-2-N-[(2,4-dichlorophenyl)methyl]-1-N-hexyl-5-oxopyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NCCCCCC)C=CC(=C1)Cl ZHLIEDIGONTFNL-INIZCTEOSA-N 0.000 description 1
- QRXBZZGWHSIKSB-HNNXBMFYSA-N (2S)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxo-1-N-pentylpyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NCCCCC)C=CC(=C1)Cl QRXBZZGWHSIKSB-HNNXBMFYSA-N 0.000 description 1
- QXQRQPMEMKOVPH-INIZCTEOSA-N (2S)-2-N-[(2,4-dichlorophenyl)methyl]-5-oxo-1-N-phenylpyrrolidine-1,2-dicarboxamide Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NC2=CC=CC=C2)C=CC(=C1)Cl QXQRQPMEMKOVPH-INIZCTEOSA-N 0.000 description 1
- NKBIFAZUYHFSSY-INIZCTEOSA-N (2S)-2-N-benzyl-5-oxo-1-N-phenylpyrrolidine-1,2-dicarboxamide Chemical compound C(C1=CC=CC=C1)NC(=O)[C@H]1N(C(CC1)=O)C(=O)NC1=CC=CC=C1 NKBIFAZUYHFSSY-INIZCTEOSA-N 0.000 description 1
- LNAANPQWSBPUFK-JTQLQIEISA-N (2S)-N-(cyclohexylmethyl)-5-oxopyrrolidine-2-carboxamide Chemical compound C1(CCCCC1)CNC(=O)[C@H]1NC(CC1)=O LNAANPQWSBPUFK-JTQLQIEISA-N 0.000 description 1
- GHUJJDBYOCSMKA-JTQLQIEISA-N (2S)-N-[(2-chlorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide Chemical compound Clc1ccccc1CNC(=O)[C@@H]1CCC(=O)N1 GHUJJDBYOCSMKA-JTQLQIEISA-N 0.000 description 1
- FDVVJEPKPGTLGO-NSHDSACASA-N (2S)-N-[2-(2,4-dichlorophenyl)ethyl]-5-oxopyrrolidine-2-carboxamide Chemical compound ClC1=C(C=CC(=C1)Cl)CCNC(=O)[C@H]1NC(CC1)=O FDVVJEPKPGTLGO-NSHDSACASA-N 0.000 description 1
- MDCKMKIRZIXFCH-JTQLQIEISA-N (2s)-n-benzyl-5-oxopyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NC(=O)CC1)NCC1=CC=CC=C1 MDCKMKIRZIXFCH-JTQLQIEISA-N 0.000 description 1
- SRSHBZRURUNOSM-DEOSSOPVSA-N (4-chlorophenyl) (1s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1[C@H]1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OC1=CC=C(Cl)C=C1 SRSHBZRURUNOSM-DEOSSOPVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- WLNAHQZFPSSVTP-UHFFFAOYSA-N 1,2-dichloro-4-(isocyanatomethyl)benzene Chemical compound ClC1=CC=C(CN=C=O)C=C1Cl WLNAHQZFPSSVTP-UHFFFAOYSA-N 0.000 description 1
- MRZLMRUZKMDDHV-UHFFFAOYSA-N 1,3-bis(6-chloropyridin-3-yl)urea Chemical compound C1=NC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)N=C1 MRZLMRUZKMDDHV-UHFFFAOYSA-N 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- FYZNIJZDOYFEFI-UHFFFAOYSA-N 1-N-propan-2-ylpyrrolidine-1,2-dicarboxamide Chemical compound CC(C)NC(=O)N1CCCC1C(N)=O FYZNIJZDOYFEFI-UHFFFAOYSA-N 0.000 description 1
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
- GOOVAYJIVMBWPP-UHFFFAOYSA-N 1-bromo-2-isocyanatobenzene Chemical compound BrC1=CC=CC=C1N=C=O GOOVAYJIVMBWPP-UHFFFAOYSA-N 0.000 description 1
- NOHQUGRVHSJYMR-UHFFFAOYSA-N 1-chloro-2-isocyanatobenzene Chemical compound ClC1=CC=CC=C1N=C=O NOHQUGRVHSJYMR-UHFFFAOYSA-N 0.000 description 1
- ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 1
- VVNMGFXOVZRKQF-UHFFFAOYSA-N 1-iodo-2-isocyanatobenzene Chemical compound IC1=CC=CC=C1N=C=O VVNMGFXOVZRKQF-UHFFFAOYSA-N 0.000 description 1
- WRAZHLRMDRTLOZ-UHFFFAOYSA-N 1-isocyanato-2,4-dimethoxybenzene Chemical compound COC1=CC=C(N=C=O)C(OC)=C1 WRAZHLRMDRTLOZ-UHFFFAOYSA-N 0.000 description 1
- NRSSOFNMWSJECS-UHFFFAOYSA-N 1-isocyanato-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC(C(F)(F)F)=C1 NRSSOFNMWSJECS-UHFFFAOYSA-N 0.000 description 1
- SXJYSIBLFGQAND-UHFFFAOYSA-N 1-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(N=C=O)=C1 SXJYSIBLFGQAND-UHFFFAOYSA-N 0.000 description 1
- WIRPZDICFIIBRF-UHFFFAOYSA-N 1-isocyanato-4-phenylbenzene Chemical compound C1=CC(N=C=O)=CC=C1C1=CC=CC=C1 WIRPZDICFIIBRF-UHFFFAOYSA-N 0.000 description 1
- YIDSTEJLDQMWBR-UHFFFAOYSA-N 1-isocyanatododecane Chemical compound CCCCCCCCCCCCN=C=O YIDSTEJLDQMWBR-UHFFFAOYSA-N 0.000 description 1
- VRVUKQWNRPNACD-UHFFFAOYSA-N 1-isocyanatopentane Chemical compound CCCCCN=C=O VRVUKQWNRPNACD-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IOASODGEZSLHHY-UHFFFAOYSA-N 1-thia-4-azaspiro[4.5]decane;hydrochloride Chemical compound Cl.N1CCSC11CCCCC1 IOASODGEZSLHHY-UHFFFAOYSA-N 0.000 description 1
- FUIUATRKBRZCQD-UHFFFAOYSA-N 2,4-dichloro-1-(isocyanatomethyl)benzene Chemical compound ClC1=CC=C(CN=C=O)C(Cl)=C1 FUIUATRKBRZCQD-UHFFFAOYSA-N 0.000 description 1
- OLBJNSPBWLCTOT-UHFFFAOYSA-N 2,4-dichloro-1-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C(Cl)=C1 OLBJNSPBWLCTOT-UHFFFAOYSA-N 0.000 description 1
- WHENXACISRCOHK-UHFFFAOYSA-N 2-chloro-5-isocyanatopyridine Chemical compound ClC1=CC=C(N=C=O)C=N1 WHENXACISRCOHK-UHFFFAOYSA-N 0.000 description 1
- HJHZRZFONUPQAA-UHFFFAOYSA-N 2-isocyanato-1,3,5-trimethylbenzene Chemical compound CC1=CC(C)=C(N=C=O)C(C)=C1 HJHZRZFONUPQAA-UHFFFAOYSA-N 0.000 description 1
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- QVLWPBIUVXZGRK-UHFFFAOYSA-N 2-isocyanatothiophene Chemical compound O=C=NC1=CC=CS1 QVLWPBIUVXZGRK-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 description 1
- GTGSCCFGFIPCOA-UHFFFAOYSA-N 4-chloro-3-isocyanatopyridine Chemical compound Clc1ccncc1N=C=O GTGSCCFGFIPCOA-UHFFFAOYSA-N 0.000 description 1
- WGOIHPRRFBCVBZ-UHFFFAOYSA-N 5-oxopyrrolidine-2-carboxamide Chemical class NC(=O)C1CCC(=O)N1 WGOIHPRRFBCVBZ-UHFFFAOYSA-N 0.000 description 1
- BJSCOTHGFJMOOE-UHFFFAOYSA-N 5-oxopyrrolidine-3-carboxamide Chemical class NC(=O)C1CNC(=O)C1 BJSCOTHGFJMOOE-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229910014265 BrCl Inorganic materials 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- WWLFDQXODGJIED-CFMCSPIPSA-N CC(C)NC(N([C@@H](CC1)C(NCc(ccc(Cl)c2)c2Cl)O)C1=O)=O Chemical compound CC(C)NC(N([C@@H](CC1)C(NCc(ccc(Cl)c2)c2Cl)O)C1=O)=O WWLFDQXODGJIED-CFMCSPIPSA-N 0.000 description 1
- SCKZAIVRYUIJIV-UHFFFAOYSA-N CC(C=C1C)=CC(C)=C1NC(N(CCC1)C1C(N)=O)=O Chemical compound CC(C=C1C)=CC(C)=C1NC(N(CCC1)C1C(N)=O)=O SCKZAIVRYUIJIV-UHFFFAOYSA-N 0.000 description 1
- ILQKVYWXORKVEX-UHFFFAOYSA-N CC(CC1)(C(NCc(c(Cl)c2)ccc2Cl)=O)N(C(Nc(cccc2)c2I)=O)C1=O Chemical compound CC(CC1)(C(NCc(c(Cl)c2)ccc2Cl)=O)N(C(Nc(cccc2)c2I)=O)C1=O ILQKVYWXORKVEX-UHFFFAOYSA-N 0.000 description 1
- FBQGDAINAMMBLW-UHFFFAOYSA-N CC(CC1)(C(NCc(ccc(Cl)c2)c2Cl)=O)N(C(NC(CC2)=CC=C2Cl)=O)C1=O Chemical compound CC(CC1)(C(NCc(ccc(Cl)c2)c2Cl)=O)N(C(NC(CC2)=CC=C2Cl)=O)C1=O FBQGDAINAMMBLW-UHFFFAOYSA-N 0.000 description 1
- QRDMVAAGWVWFPP-UHFFFAOYSA-N CC(CC=C1CNCC(CC2)(C=O)N(C(NCC(C=CC3Cl)=CC3Cl)=O)C2=O)C=C1Cl Chemical compound CC(CC=C1CNCC(CC2)(C=O)N(C(NCC(C=CC3Cl)=CC3Cl)=O)C2=O)C=C1Cl QRDMVAAGWVWFPP-UHFFFAOYSA-N 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- ARQBKQXWJPAYJO-SFHVURJKSA-N Cc(cc1C)cc(C)c1NC(N([C@@H](CC1)C(NCc(c(Cl)c2)ccc2Cl)=O)C1=O)=O Chemical compound Cc(cc1C)cc(C)c1NC(N([C@@H](CC1)C(NCc(c(Cl)c2)ccc2Cl)=O)C1=O)=O ARQBKQXWJPAYJO-SFHVURJKSA-N 0.000 description 1
- PFNAIJOCPOXIKZ-AWEZNQCLSA-N Cc1cc(Cl)c(CNC([C@H](CC2)N(C(Nc3ccc[s]3)=O)C2=O)=O)cc1 Chemical compound Cc1cc(Cl)c(CNC([C@H](CC2)N(C(Nc3ccc[s]3)=O)C2=O)=O)cc1 PFNAIJOCPOXIKZ-AWEZNQCLSA-N 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- QQDQUZMOUMIWPT-QFIPXVFZSA-N ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NCCCCCCCCCCCC)C=CC(=C1)Cl Chemical compound ClC1=C(CNC(=O)[C@H]2N(C(CC2)=O)C(=O)NCCCCCCCCCCCC)C=CC(=C1)Cl QQDQUZMOUMIWPT-QFIPXVFZSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000272190 Falco peregrinus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101001030243 Homo sapiens Myosin-7 Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010023852 KIR2DL2 Receptors Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 101150104680 MCH1 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100182715 Mus musculus Ly6c2 gene Proteins 0.000 description 1
- 101100182723 Mus musculus Ly6g gene Proteins 0.000 description 1
- 102100038934 Myosin-7 Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- JZIGGCUPZSGUSI-UHFFFAOYSA-N N-[(2,4-dichlorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide Chemical compound Clc1ccc(CNC(=O)C2CCC(=O)N2)c(Cl)c1 JZIGGCUPZSGUSI-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- AXZKFDBUWHLDMO-UHFFFAOYSA-N NC(C(CCC1)N1C(NC1=CC=CS1)=O)=O Chemical compound NC(C(CCC1)N1C(NC1=CC=CS1)=O)=O AXZKFDBUWHLDMO-UHFFFAOYSA-N 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- INGDAWAHUQKCPO-UHFFFAOYSA-N O=C(C(CC1)N(C(Nc2ccc[s]2)=O)C1=O)NCc(c(Cl)c1)ccc1Cl Chemical compound O=C(C(CC1)N(C(Nc2ccc[s]2)=O)C1=O)NCc(c(Cl)c1)ccc1Cl INGDAWAHUQKCPO-UHFFFAOYSA-N 0.000 description 1
- QHTWVFFQTHJOPL-INIZCTEOSA-N O=C([C@H](CC1)N(C(Nc2cccc(C(F)(F)F)c2)=O)C1=O)NCc(ccc(Cl)c1)c1Cl Chemical compound O=C([C@H](CC1)N(C(Nc2cccc(C(F)(F)F)c2)=O)C1=O)NCc(ccc(Cl)c1)c1Cl QHTWVFFQTHJOPL-INIZCTEOSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101150065089 P2rx7 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101100382379 Rattus norvegicus Cap1 gene Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- LTEJRLHKIYCEOX-OCCSQVGLSA-N brivanib alaninate Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](C)OC(=O)[C@H](C)N)=C1 LTEJRLHKIYCEOX-OCCSQVGLSA-N 0.000 description 1
- 229950005993 brivanib alaninate Drugs 0.000 description 1
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical group C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ANJPRQPHZGHVQB-UHFFFAOYSA-N hexyl isocyanate Chemical compound CCCCCCN=C=O ANJPRQPHZGHVQB-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 201000010552 hypertrophic cardiomyopathy 1 Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031037 interleukin-18 production Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- FYJROXRIVQPKRY-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 FYJROXRIVQPKRY-UHFFFAOYSA-N 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960005492 pazopanib hydrochloride Drugs 0.000 description 1
- MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 description 1
- FWZLYKYJQSQEPN-SKLAJPBESA-N peregrine Chemical compound OC1[C@H]2[C@@H]3C4([C@@H]5C6OC(C)=O)C(OC)CC[C@@]5(C)CN(CC)[C@H]4C6[C@@]2(OC)C[C@H](OC)[C@H]1C3 FWZLYKYJQSQEPN-SKLAJPBESA-N 0.000 description 1
- FWZLYKYJQSQEPN-UHFFFAOYSA-N peregrine Natural products OC1C2C3C4(C5C6OC(C)=O)C(OC)CCC5(C)CN(CC)C4C6C2(OC)CC(OC)C1C3 FWZLYKYJQSQEPN-UHFFFAOYSA-N 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- RVEDFFORAVMBLV-UHFFFAOYSA-N pyrrolidine-1,2-dicarboxamide Chemical compound NC(=O)C1CCCN1C(N)=O RVEDFFORAVMBLV-UHFFFAOYSA-N 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- VLQLUZFVFXYXQE-USRGLUTNSA-M rigosertib sodium Chemical compound [Na+].COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC([O-])=O)=C1 VLQLUZFVFXYXQE-USRGLUTNSA-M 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
R1は、C1〜C14アルキル、シクロアルキル基、アリール基、アラルキル基又はヘテロアリール基を表し、ここで、前記アリール基、アラルキル基又はヘテロアリール基は、非置換であり、又は
- ハロゲン原子、
- C1〜C6アルコキシ基、
- C1〜C6アルキル基、及び
- C1〜C6ハロゲノアルキル基
から選ばれる少なくとも1つの基で置換されており、
R2は、アリール基、アラルキル基又はシクロアルキル基を表し、ここで、前記アリール基又は前記アラルキル基は、非置換であり、又はハロゲン原子から選ばれる少なくとも1つの基で置換されている)
の化合物、それらの鏡像異性体及び医薬として許容されるそれらの塩から選ばれる化合物に関する。
- ハロゲン原子、
- C1〜C6アルコキシ基、
- C1〜C6アルキル基、及び
- C1〜C6ハロゲノアルキル基
から選ばれる少なくとも1つの基で置換されている)
の化合物、それらの鏡像異性体及び医薬として許容されるそれらの塩から選ばれる。
を有する。
を有する。
好ましくは、アラルキルは、置換されている又は非置換の、ベンジル又はフェネチルである。
P2X受容体のうちのいずれも発現しない培養細胞を、mP2rx7遺伝子についてコードした発現ベクターでトランスフェクトする。大きい開孔を、細胞死を測定するのに適切なプローブ(例えばインビトロゲンからのTopro3)でアッセイする。各実験において、試験化合物の存在下、細胞をBzATP(3'-O-(4-ベンゾイル)ベンゾイルATP)で処置する、又は処置しない。示されているとき、細胞死を測定するのに適切なプローブ(例えばTopro3)を添加する。
蛍光をフローサイトメトリーによりアッセイする。
各化合物を、BzATPの不在下又は存在下で試験する。
試験化合物が、BzATPの存在下で、BzATP単独と比較して、更に試験化合物単独と比較して、大きい開孔(すなわち細胞死)を有意に増加させる場合、その試験化合物はP2RX7モジュレーターである。
本発明による式(I)[及び(I')、(II)、(II')]の化合物は、実行しやすい方法によって調製することができる。前記方法は、以下の通りであり、実施例1に示す通りである:
5-オキソピロリジン-2-カルボキサミド誘導体又は5-オキソピロリジン-3-カルボキサミド誘導体[及び、特に式(II')の事例では、N-(2,4-ジクロロベンジル)-5-オキソピロリジン-(2S)-カルボキサミド]と、対応するイソシアネートとのトルエン等溶媒中混合物を、窒素雰囲気下、還流下で、いくらかの時間(例えば1〜24時間)撹拌した。
上で説明した通り、更に実施例で示す通り、発明者らは、本発明の化合物が療法において有用であることを明示した。
a)式(I)の化合物[好ましくは式(I')、(II)若しくは(II')の化合物]、それらの鏡像異性体及び医薬として許容されるそれらの塩から選ばれる少なくとも1種の化合物と、
b)少なくとも1種の付加的な療法と
を含む、がんの治療及び/又は予防における、同時の、別々の又は順次の使用のための併用製品としての製品にも関する。
a)式(I)の化合物[好ましくは式(I')、(II)若しくは(II')の化合物]、それらの鏡像異性体及び医薬として許容されるそれらの塩から選ばれる少なくとも1種の化合物と、
b)抗チェックポイント抗体から選ばれる、好ましくは抗PD1抗体から選ばれる、より好ましくはニボルマブ及びペンブロリズマブから選ばれる少なくとも1種の付加的な療法と
を含む、
がんの治療及び/又は予防における、同時の、別々の又は順次の使用のための併用製品としての、製品にも関する。
- 抗代謝剤、例えばアザチオプリン、シタラビン、リン酸フルダラビン、フルダラビン、ゲムシタビン、シタラビン、クラドリビン、カペシタビン6-メルカプトプリン、6-チオグアニン、メトトレキセート、5-フルオロウラシル及びヒドロキシ尿素、
- アルキル化剤、例えばメルファラン、ブスルファン、シスプラチン、カルボプラチン、シクロホスファミド、イフォスファミド、デカラバジン、フォテムスチン、プロカルバジン、クロラムブシル、チオテパ、ロムスチン、テモゾロミド、
- 抗有糸分裂剤、例えばビノレルビン、ビンクリスチン、ビンブラスチン、ドセタキセル、パクリタクセル、
- トポイソメラーゼ阻害剤、例えばドキソルビンシン、アムサクリン、イリノテカン、ダウノルビシン、エピルビシン、ミトマイシン、ミトキサントロン、イダルビシン、テニポシド、エトポシド、トポテカン、
- 抗生物質、例えばアクチノマイシン及びブレオマイシン、
- アスパラギナーゼ、
- アントラシクリン又はタキサン。
化合物HEI 2314、HEI 2328、HEI 2333、HEI 2336及びHEI 3090の合成
本発明の化合物の合成のための一般手順
N-(2,4-ジクロロベンジル)-5-オキソピロリジン-2-カルボキサミド(1当量)と、対応するイソシアネート(1当量)とのトルエン中混合物を、窒素雰囲気下、還流下で1〜24時間撹拌した。得られた混合物を、MeOH中、直接の結晶化により精製して、純粋な化合物を得た。
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(0.90g、3.3mmol)及びフェニルイソシアネート(0.39g、3.3mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2347を収率81%で得た(1.05g、2.7mmol)。mp 214〜217℃(MeOH); TLC Rf (CH2Cl2/MeOH:98/2) 0.9; 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.98-2.10 (m, 1H, CH2CH2CH), 2.38-2.48 (m, 1H, CH2CH2CH), 2.60-2.81 (m, 2H, CH2CH2CH), 5.08 (dd, J = 5.6, 2.4 Hz, 1H, CH2CH2CH), 7.10 (t, J = 7.2 Hz, 1H, ArH), 7.34 (t, J = 7.2 Hz, 2H, ArH), 7.42 (dd, J = 8.8, 2.4 Hz, 1H, ArH), 7.51 (d, J = 7.2 Hz, 2H, ArH), 7.68 (d, J = 2.4 Hz, 1H, ArH), 7.73 (d, J = 8.8 Hz, 1H, ArH), 10.08 (br s, 1H, NH), 10.51 (br s, 1H, NH); 13C NMR (DMSO-d6, 100 MHz) δ ppm 21.4 (CH2), 31.7 (CH2), 58.8 (CH), 119.6 (2 CH), 123.9 (CH), 127.3 (CH), 127.5 (CH), 127.6 (CH), 129.0 (C), 129.1 (2 CH), 129.7 (C), 133.6 (C), 137.2 (C), 149.3 (C), 170.2 (C), 177.8 (C); LC-MS (APCI+) m/z: 392.1 (MH+), tr 4.38分; IR ν (cm-1): 3275, 2922, 1723, 1693, 1662, 1559, 1473, 1219, 1100, 819; 元素分析:C18H15Cl2N3O3の計算値: C, 55.12; H, 3.85; N, 10.71. 実測値: C, 54.91; H, 3.89; N, 10.75%.
(S)-N-(2-クロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.43g、5.6mmol)及びアダマンチルイソシアネート(1.00g、5.6mmol)を使用して一般手順に従った。所望の生成物をシリカカラム(EtOAc/n-ヘプタン 4/6〜6/4)で精製して、純粋なHEI_2298を白色固体として収率62%で得た(1.50g、3.5mmol)。mp 79〜80℃(EtOAc/n-ヘプタン);TLC Rf (CH2Cl2/MeOH:98/2) 0.6; 1H NMR (CDCl3, 400 MHz) δ ppm 1.68 (s, 6H, ADM-H), 1.98 (s, 6H, ADM-H), 2.09 (s, 3H, ADM-H), 2.10-2.18 (m, 1H, CH2CH2CH), 2.38-2.45 (m, 1H, CH2CH2CH), 2.46-2.52 (m, 1H, CH2CH2CH), 2.89-2.97 (m, 1H, CH2CH2CH), 4.51 (dd, J = 14.2, 5.0 Hz, 1H, NHCH2), 4.55 (dd, J = 14.2, 5.0 Hz, 1H, NHCH2), 4.76 (dd, J = 8.8, 1.6 Hz, 1H, CH2CH2CH), 7.14 (t, J = 5.0 Hz, 1H, ArH), 7.21 (m, 2H, ArH), 7.35 (m, 2H, ArH及びNHCH2), 8.39 (br s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.1 (CH2), 29.5 (2 CH2), 32.9 (CH2), 36.4 (2 CH2), 41.6 (CH2), 41.7 (2 CH2), 51.9 (CH), 59.0 (CH), 127.1 (2 CH), 128.9 (2 CH), 129.6 (2 CH), 129.7 (C), 133.6 (C), 135.4 (C), 151.4 (C), 170.5 (C), 177.3 (C); LC-MS (APCI+) m/z: 430.1 (MH+), tr 4.60分; IR ν (cm-1): 3289, 2906, 2849, 1715, 1663, 1538, 1223, 1033, 749; 元素分析:C23H28ClN3O3の計算値C, 64.25; H, 6.56; N, 9.77. 実測値: C, 64.32; H, 6.89; N, 9.58%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.97g、6.9mmol)及びn-ブチルイソシアネート(0.75g、7.6mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2535を収率71%で得た(1.89g、4.9mmol)。mp 162〜163℃(MeOH);TLC Rf (CH2Cl2/MeOH:99/1) 0.4; 1H NMR (CDCl3, 400 MHz) δ ppm 0.92 (t, J = 7.4 Hz, 3H, CH3CH2), 1.35 (m, 2H, CH3CH2), 1.51 (五重線, J = 7.8 Hz, 2H, CH2CH2CH2), 2.12 (td, J = 18.0, 11.3, 8.7 Hz, 1H, CH2CH2CH), 2.39 (m, 1H, CH2CH2CH), 2.49 (td, J = 17.7, 9.4, 2.0 Hz, 1H, CH2CH2CH), 2.92 (td, J = 17.5, 11.3, 9.4 Hz, 1H, CH2CH2CH), 3.27 (dq, J = 7.1, 1.6 Hz, 2H, CH2NHCO), 4.47 (dd, J = 6.0, 2.8 Hz, 2H, NHCH2Ar), 4.75 (dd, J = 9.0, 1.6 Hz, 1H, CH2CH2CH), 7.08 (br t, J = 5.7 Hz, 1H, NHCH2Ar), 7.20 (dd, J = 8.2, 2.3 Hz, 1H, ArH), 7.29 (d, J = 8.2 Hz, 1H, ArH), 7.36 (d, J = 2.0 Hz, 1H, ArH), 8.43 (br t, J = 5.9 Hz, 1H, NHCH2CH2); 13C NMR (CDCl3, 100 MHz) δ ppm 13.7 (CH3), 20.0 (CH2), 21.1 (CH2), 31.6 (CH2), 32.5 (CH2), 39.7 (CH2), 41.1 (CH2), 59.0 (CH), 127.3 (CH), 129.3 (CH), 130.6 (CH), 133.9 (C), 134.0 (C), 134.1 (C), 153.1 (C), 170.3 (C), 177.2 (C); IR ν (cm-1): 3270, 1712, 1683, 1649, 1465, 1236, 1101, 810, 653; 元素分析:C17H21Cl2N3O3の計算値: C, 52.86; H, 5.48; N 10.88. 実測値: C, 52.50; H, 5.88; N, 11.11%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.73g、6.0mmol)及びn-ペンチルイソシアネート(0.75g、6.6mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2541を収率70%で得た(1.67g、4.2mmol)。mp 159〜160℃(MeOH);TLC Rf (CH2Cl2/MeOH:99/1) 0.7; 1H NMR (CDCl3, 400 MHz) δ ppm 0.96 (t, J = 6.9 Hz, 3H, CH3CH2), 1.39 (m, 4H, CH2(CH2)2CH2), 1.59 (五重線, J = 7.3 Hz, 2H, CH3CH2), 2.19 (m, 1H, CH2CH2CH), 2.41 (m, 1H, CH2CH2CH), 2.56 (td, J = 17.6, 9.4, 1.9 Hz, 1H, CH2CH2CH), 2.99 (td, J = 17.6, 11.3, 9.3 Hz, 1H, CH2CH2CH), 3.32 (qd, J = 7.4, 2.8 Hz, 2H, CH2(CH2)3), 4.54 (dd, J = 7.5, 6.3 Hz, 2H, NHCH2Ar), 4.82 (dd, J = 9.1, 1.6 Hz, 1H, CH2CH2CH), 7.18 (br t, J = 6.0 Hz, 1H, NHCH2Ar), 7.26 (dd, J = 8.2, 2.4 Hz, 1H, ArH), 7.36 (d, J = 8.2 Hz, 1H, ArH), 7.43 (d, J = 2.3 Hz, 1H, ArH), 8.51 (br t, J = 5.7 Hz, 1H, NH(CH2)2); 13C NMR (CDCl3, 100 MHz) δ ppm 13.9 (CH3), 21.2 (CH2), 22.3 (CH2), 29.0 (CH2), 29.2 (CH2), 32.5 (CH2), 40.0 (CH2), 41.1 (CH2), 59.0 (CH), 127.3 (CH), 129.3 (CH), 130.5 (CH), 133.9 (C), 134.1 (C), 153.1 (C), 170.4 (C), 177.2 (2 C); IR ν (cm-1): 3318, 1710, 1664, 1561, 1530, 1358, 1259, 830, 630; 元素分析:C18H23Cl2N3O3の計算値: C, 54.01; H, 5.79; N, 10.50. 実測値: C, 53.70; H, 5.95; N, 10.59%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.54g、5.4mmol)及びn-ヘキシルイソシアネート(0.75g、5.9mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2534を収率66%で得た(1.47g、3.5mmol)。mp 141〜142℃(MeOH);TLC Rf (CH2Cl2/MeOH:99/1) 0.4; 1H NMR (CDCl3, 400 MHz) δ 0.90 (t, J = 6.9 Hz, 3H, CH3CH2), 1.32 (m, 6H, CH2(CH2)3CH2), 1.54 (q, J = 6.7 Hz, 2H, CH3CH2), 2.14 (m, 1H, CH2CH2CH), 2.41 (m, 1H, CH2CH2CH), 2.52 (td, J = 17.5, 9.3, 2.0 Hz, 1H, CH2CH2CH), 2.94 (td, J = 17.9, 11.4, 9.6 Hz, 1H, CH2CH2CH), 3.82 (dq, J = 7.3, 1.7 Hz, 2H, CH2(CH2)4), 4.50 (dd, J = 5.8, 4.5 Hz, 2H, NHCH2Ar), 4.77 (dd, J = 8.6, 1.4 Hz, 1H, CH2CH2CH), 7.11 (br t, J = 5.5 Hz, 1H, NHCH2Ar), 7.22 (dd, J = 8.2, 2.0 Hz, 1H, ArH), 7.31 (d, J = 8.2 Hz, 1H, ArH), 7.39 (d, J = 2.1 Hz, 1H, ArH), 8.46 (br t, J = 5.7 Hz, 1H, NH(CH2)2); 13C NMR (CDCl3, 100 MHz) δ ppm 14.0 (CH3), 21.1 (CH2), 22.5 (CH2), 26.5 (CH2), 29.5 (CH2), 31.4 (CH2), 32.5 (CH2), 40.1 (CH2), 41.1 (CH2), 59.0 (CH), 127.3 (CH), 129.3 (CH), 130.6 (CH), 133.9 (C), 134.0 (C), 134.1 (C), 153.1 (C), 170.3 (C), 177.2 (C); IR ν (cm-1): 3313, 2926, 2865, 1708, 1664, 1355, 1253, 1153, 829, 654; 元素分析:C19H25Cl2N3O3の計算値: C, 55.08; H, 6.08; N 10.14. 実測値: C, 55.02; H, 6.15; N, 10.27%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(0.93g、3.2mmol)及びn-ドデシルイソシアネート(0.75g、3.5mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2542を収率49%で得た(0.78g、1.6mmol)。mp 124〜125℃(MeOH);TLC Rf (CH2Cl2/MeOH:99/1) 0.8; 1H NMR (CDCl3, 400 MHz) δ ppm 0.88 (t, J = 6.6 Hz, 3H, CH3CH2), 1.26 (m, 18H, CH2(CH2)9CH2), 1.53 (五重線, J = 6.7 Hz, 2H, CH3CH2), 2.13 (m, 1H, CH2CH2CH), 2.40 (m, 1H, CH2CH2CH), 2.51 (td, J = 17.6, 9.3, 1.8 Hz, 1H, CH2CH2CH), 2.93 (td, J = 17.7, 11.3, 9.5 Hz, 1H, CH2CH2CH), 3.29 (q, J = 7.2 Hz, 2H, CH2(CH2)10), 4.48 (dd, J = 6.2 Hz, 2H, NHCH2Ar), 4.76 (dd, J = 8.9, 1.2 Hz, 1H, CH2CH2CH), 7.11 (br t, J = 5.9 Hz, 1H, NHCH2Ar), 7.21 (dd, J = 8.3, 2.2 Hz, 1H, ArH), 7.30 (d, J = 8.2 Hz, 1H, ArH), 7.37 (d, J = 2.1 Hz, 1H, ArH), 8.45 (br t, J = 6.0 Hz, 1H, NH(CH2)2); 13C NMR (CDCl3, 100 MHz) δ ppm 14.1 (CH3), 21.1 (CH2), 22.7 (CH2), 26.9 (CH2), 29.3 (CH2), 29.3 (CH2), 29.5 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 31.9 (CH2), 32.5 (CH2), 40.1 (CH2), 41.1 (CH2), 59.0 (CH), 127.3 (CH), 129.3 (CH), 130.5 (CH), 133.9 (C), 133.9 (C), 134.1 (C), 153.1 (C), 170.3 (C), 177.2 (C); IR ν (cm-1): 3302, 2918, 2850, 1718, 1658, 1541, 1349, 1251, 832, 648; 元素分析:C25H37Cl2N3O3の計算値: C, 60.2; H, 7.48; N, 8.43. 実測値: C, 59.8; H, 7.5; N, 8.5%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(2.30g、8.0mmol)及びプロパン-2-イルイソシアネート(0.75g、8.8mmol)を使用して一般手順に従った。所望の生成物をシリカカラム(EtOAc/n-ヘプタン 1/9〜1/0)で精製して、純粋なHEI_2537を黄色固体として収率55%で得た(1.65g、4.4mmol)。mp 111〜112℃(EtOAc/n-ヘプタン);TLC Rf (CH2Cl2/MeOH:99/1) 0.4; 1H NMR (CDCl3, 400 MHz) δ ppm 1.20 (dd, J = 6.5, 2.7 Hz, 6H, (CH3)2CH), 2.12 (td, J = 18.1, 11.4, 9.0 Hz, 1H, CH2CH2CH), 2.38 (m, 1H, CH2CH2CH), 2.50 (td, J = 17.5, 9.3, 1.8 Hz, 1H, CH2CH2CH), 2.86 (td, J = 17.6, 11.4, 9.4 Hz, 1H, CH2CH2CH), 3.95 (m, 1H, (CH3)2CH), 4.48 (d, J = 6.2 Hz, 2H, NHCH2), 4.76 (dd, J = 8.6, 1.4 Hz, 1H, CH2CH2CH), 7.18 (br t, J = 6.2 Hz, 1H, NHCH2), 7.20 (dd, J = 8.3, 2.2 Hz, 1H, ArH), 7.30 (d, J = 8.0 Hz, 1H, ArH), 7.37 (d, J = 1.8 Hz, 1H, ArH), 8.33 (br t, J = 5.7 Hz, 1H, NHCH(CH3)2); 13C NMR (CDCl3, 100 MHz) δ ppm 21.1 (CH2), 22.6 (CH3), 22.7 (CH3), 32.6 (CH2), 41.1 (CH2), 42.4 (CH), 59.0 (CH), 127.3 (CH), 129.3 (CH), 130.5 (CH), 133.9 (C), 134.1 (C), 152.3 (C), 170.4 (C), 177.2 (2 C); IR ν (cm-1): 3317, 1703, 1643, 1523, 1226, 817, 590; 元素分析:C16H19Cl2N3O3の計算値: C, 51.63; H, 5.14; N, 11.29. 実測値: C, 51.46; H, 5.55; N, 11.70%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.97g、6.9mmol)及びtert-ブチルイソシアネート(0.75g、7.6mmol)を使用して一般手順に従った。所望の生成物をシリカカラム(EtOAc/n-ヘプタン 3/7〜1/0)で精製して、純粋なHEI_2538を白色固体として収率36%で得た(0.95g、2.5mmol)。mp 99〜101℃(EtOAc/n-ヘプタン);TLC Rf (CH2Cl2/MeOH:99/1) 0.7; 1H NMR (CDCl3, 400 MHz) δ ppm 1.35 (s, 9H, C(CH3)3), 2.05-2.16 (m, 1H, CH2CH2CH), 2.36 (dd, J = 11.9, 2.0 Hz, 1H, CH2CH2CH), 2.49 (ddd, J = 17.6, 9.4, 2.0 Hz, 1H, CH2CH2CH), 2.93 (ddd, J = 17.7, 11.4, 9.4 Hz, 1H, CH2CH2CH), 4.42 (dd, J = 15.2, 5.9 Hz, 1H, NHCH2), 4.53 (dd, J = 15.7, 6.7 Hz, 1H, NHCH2), 4.76 (dd, J = 8.6, 1.6 Hz, 1H, CH2CH2CH), 7.18 (dd, J = 8.2, 2.1 Hz, 1H, ArH), 7.20 (br s, 1H, NHCH2), 7.29 (d, J = 8.2 Hz, 1H, ArH), 7.36 (d, J = 2.3 Hz, 1H, ArH), 8.48 (br s, 1H, NHC(CH3)3); 13C NMR (CDCl3, 100 MHz) δ ppm 20.9 (CH2), 28.7 (3 CH3), 32.7 (CH2), 41.0 (CH2), 51.1 (C), 58.8 (CH), 127.2 (CH), 129.2 (CH), 130.3 (CH), 133.8 (C), 133.9 (C), 134.0 (C), 151.7 (C), 170.6 (C), 177.1 (C); IR ν (cm-1): 3280, 1717, 1689, 1656, 1547, 1267, 1191, 824, 657; 元素分析:C17H21Cl2N3O3の計算値: C, 52.86; H, 5.48; N, 10.88. 実測値: C, 52.63; H, 6.03; N, 10.91%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(2.00g、7.0mmol)及びシクロヘキシルイソシアネート(0.87g、7.0mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2315を収率82%で得た(2.35g、5.7mmol)。mp 137〜142℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2) 0.5; 1H NMR (CDCl3, 400 MHz) δ ppm 1.15-1.45 (m, 5H, シクロヘキサ-H), 1.59 (m, 1H, シクロヘキサ-H), 1.71 (m, 2H, シクロヘキサ-H), 1.88 (m, 2H, シクロヘキサ-H), 2.05-2.20 (m, 1H, シクロヘキサ-H), 2.25-2.40 (m, 1H, CH2CH2CH), 2.42-2.56 (m, 1H, CH2CH2CH), 2.82-2.96 (m, 1H, CH2CH2CH), 3.62-3.66 (m, 1H, CH2CH2CH), 4.44 (dd, J = 15.2, 5.6 Hz, 1H, NHCH2), 4.51 (dd, J = 15.2, 5.6 Hz, 1H, NHCH2), 4.73-4.79 (m, 1H, CH2CH2CH), 7.19 (dd, J = 8.4, 2.0 Hz, 1H, ArH), 7.29 (d, J = 8.4 Hz, 1H, ArH), 7.30 (br s, 1H, NHCH2), 7.37 (d, J = 2.0 Hz, 1H, ArH), 8.42 (d, J = 7.6 Hz, 1H, NHCH); 13C NMR (CDCl3, 100 MHz) δ ppm 21.2 (CH2), 24.5 (CH2), 25.4 (CH2), 32.5 (CH2), 32.7 (CH2), 32.8 (CH2), 41.0 (CH2), 49.0 (CH2), 58.9 (2CH), 127.3 (CH), 129.3 (CH), 130.5 (CH), 133.9 (C), 134.0 (C), 134.1 (C), 152.2 (C), 170.5 (C), 177.2 (C); LC-MS (APCI+) m/z: 412.0 (MH+), tr 4.45分; IR ν (cm-1): 3303, 2928, 2853, 1703, 1656, 1534, 1224; 元素分析:C19H23Cl2N3O3の計算値: C, 55.35; H, 5.62; N, 10.19. 実測値: C, 55.36; H, 6.14; N, 10.39%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.50g、5.2mmol)及びアダマンチルイソシアネート(0.93g、5.2mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2329を収率97%で得た(2.34g、5.0mmol)。mp 85〜87℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2) 0.5; 1H NMR (CDCl3, 400 MHz) δ ppm 1.64-1.70 (m, 6H, ADM-H), 1.95-1.99 (m, 6H, ADM-H), 2.00-2.16 (m, 4H, ADM-H及びCH2CH2CH), 2.30-2.40 (m, 1H, CH2CH2CH), 2.42-2.54 (m, 1H, CH2CH2CH), 2.86-2.98 (m, 1H, CH2CH2CH), 4.45 (dd, J = 15.2, 6.0 Hz, 1H, NHCH2), 4.51 (dd, J = 15.2, 6.0 Hz, 1H, NHCH2), 4.76 (dd, J = 8.8, 1.6 Hz, 1H, CH2CH2CH), 7.17 (dd, J = 8.0, 2.0 Hz, 1H, ArH), 7.26 (t, J = 6.0 Hz, 1H, NHCH2), 7.28 (d, J = 8.0 Hz, 1H, ArH), 7.36 (d, J = 2.0 Hz, 1H, ArH), 8.39 (br s, 1H, NHCH); 13C NMR (CDCl3, 100 MHz) δ ppm 21.1 (CH2), 29.5 (2CH2), 32.9 (CH2), 36.4 (2CH2), 41.1 (CH2), 41.7 (2CH2), 51.9 (CH), 59.0 (CH), 127.4 (CH), 129.4 (2CH), 130.5 (2CH), 134.0 (C), 134.1 (2C), 134.2 (C), 151.4 (C), 170.7 (C), 177.3 (C); LC-MS (APCI+) m/z: 464.2 (MH+), tr 4.80分; IR ν (cm-1): 3289, 2906, 2848, 1715, 1661, 1538, 1222, 1048, 829; 元素分析:C23H27Cl2N3O3の計算値: C, 59.49; H, 5.86; N, 9.05. 実測値: C, 59.59; H, 6.26; N, 8.71%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(0.40g、1.4mmol)及びフェニルイソシアネート(0.17g、1.4mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2339を収率76%で得た(0.43g、1.1mmol)。mp 216〜219℃(MeOH);TLC Rf (CH2Cl2/MeOH:96/4) 0.8; 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.85-1.95 (m, 1H, CH2CH2CH), 2.30-2.40 (m, 1H, CH2CH2CH), 2.58-2.79 (m, 2H, CH2CH2CH), 4.36 (m, 2H, NHCH2), 4.80 (dd, J = 9.2, 2.4 Hz, 1H, CH2CH2CH), 7.11 (t, J = 7.2 Hz, 1H, ArH), 7.35 (t, J = 7.2 Hz, 2H, ArH), 7.43-7.44 (m, 2H, ArH), 7.51 (d, J = 7.2 Hz, 2H, ArH), 7.61-7.62 (m, 1H, ArH), 8.85 (t, J = 5.6 Hz, 1H, NHCH2), 10.51 (br s, 1H, NHAr); 13C NMR (DMSO-d6, 100 MHz) δ ppm 21.4 (CH2), 31.8 (CH2), 40.0 (CH2), 58.7 (CH), 119.5 (2 CH), 123.8 (CH), 127.3 (CH), 128.6 (CH), 129.1 (2 CH), 130.1 (CH), 132.3 (C), 132.9 (C), 135.2 (C), 137.3 (C), 149.4 (C), 171.2 (C), 177.8 (C); LC-MS (APCI+) m/z: 408.1 (MH+), tr 4.37分; IR ν (cm-1): 3276, 1718, 1644, 1543, 1217, 1054, 748; 元素分析:C19H17Cl2N3O3の計算値: C, 56.17; H, 4.22; N, 10.34. 実測値: C, 56.12; H, 3.96; N, 10.24%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及びビフェニル-4-イルイソシアネート(0.75g、3.8mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2761を収率65%で得た(1.09g、2.3mmol)。mp 191〜200℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2)=0.9; 1H NMR (CDCl3, 400 MHz) δ ppm 2.16-2.30 (m, 1H, CH2CH2CH), 2.34-2.43 (m, 1H, CH2CH2CH), 2.57-2.67 (m, 1H, CH2CH2CH), 2.99-3.12 (m, 1H, CH2CH2CH), 4.52 (dd, J = 13.4, 6.7 Hz, 2H, NCH2Ar), 4.84 (d, J = 8.8 Hz, 1H, CH2CH2CH), 6.93 (s, 1H, NH), 7.21 (dd, J = 8.2, 1.8 Hz, 1H, ArH), 7.30-7.38 (m, 3H, ArH), 7.44 (t, J = 7.3 Hz, 2H, ArH), 7.52-7.61 (m, 6H, ArH), 10.60 (s, 1H, NH); 13C NMR (CDCl3, 100 MHz) δ ppm 21.2 (CH2), 29.7 (CH2), 32.6 (CH2), 41.2 (CH2), 59.2 (CH), 126.8 (2 CH), 126.9 (CH), 127.4 (CH), 127.7 (2 CH), 128.8 (2 CH), 129.4 (2 CH), 130.8 (CH), 133.8 (C), 134.1 (C), 134.2 (C), 136.2 (C), 137.5 (C), 140.5 (C), 150.5 (C), 170.2 (C), 177.5 (C); IR ν (cm-1): 3311, 3083, 1715, 1542, 1225, 764, 693; 元素分析:C25H21Cl2N3O3の計算値: C, 62.25; H, 4.39; N, 8.71. 実測値: C, 62.06; H, 4.39; N, 8.73%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(2.00g、7.0mmol)及び2-クロロフェニルイソシアネート(1.07g、7.0mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2314を収率90%で得た(2.75g、6.2mmol)。mp 213〜219℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2) 0.5; 1H NMR (CDCl3, 400 MHz) δ ppm 2.18-2.36 (m, 2H, CH2CH2CH), 2.58-2.68 (m, 1H, CH2CH2CH), 2.95-3.06 (m, 1H, CH2CH2CH), 4.47 (dd, J = 15.6, 5.6 Hz, 1H, NHCH2), 4.54 (dd, J = 15.6, 5.6 Hz, 1H, NHCH2), 4.80 (dd, J = 8.4, 2.4 Hz, 1H, CH2CH2CH), 7.06 (t, J = 7.6 Hz, 1H, NHCH2), 7.21 (dd, J = 8.0, 2.0 Hz, 1H, ArH), 7.26 (t, J = 7.6 Hz, 1H, ArH), 7.34 (d, J = 8.4 Hz, 1H, ArH), 7.37 (d, J = 2.0 Hz, 1H, ArH), 7.40 (m, 2H, ArH), 8.15 (d, J = 8.0 Hz, 1H, ArH), 11.04 (br s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.7 (CH2), 32.3 (CH2), 41.1 (CH2), 59.2 (CH), 121.8 (CH), 124.0 (C), 125.0 (CH), 127.4 (CH), 127.5 (CH), 129.4 (CH), 129.5 (CH), 130.6 (CH), 133.9 (C), 134.0 (C), 134.1 (C), 134.4 (C), 150.3 (C), 171.0 (C), 177.6 (C); LC-MS (APCI+) m/z: 442.0 (MH+), tr 4.45分; IR ν (cm-1): 3271, 1713, 1643, 1597, 1545, 1222, 1054, 749; 元素分析:C19H16Cl3N3O3の計算値: C, 51.78; H, 3.66; N, 9.53. 実測値: C, 51.80; H, 3.73; N, 9.59%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び2-ブロモフェニルイソシアネート(0.76g、3.8mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2760を収率56%で得た(0.95g、2.0mmol)。mp 217〜223℃(MeOH);TLC Rf (CH2Cl2/MeOH:95/5) 0.7; 1H NMR (CDCl3, 400 MHz) δ ppm 2.18-2.43 (m, 2H, CH2CH2CH), 2.58-2.69 (m, 1H, CH2CH2CH), 2.98-3.11 (m, 1H, CH2CH2CH), 4.52 (dd, J = 9.1, 5.7 Hz, 2H, NHCH2), 4.81 (dd, J = 9.2, 2.0 Hz, 1H, CH2CH2CH), 6.81 (br s, 1H, NHCH2), 7.00 (ddd, J = 7.9, 7.9, 1.6 Hz, 1H, ArH), 7.20 (dd, J = 8.6, 2.4 Hz, 1H, ArH), 7.30-7.35 (m, 2H, ArH), 7.37 (d, J = 2 Hz, 1H, ArH), 7.58 (dd, J = 8.1, 1.8 Hz, 1H, ArH), 8.13 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 10.94 (s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.3 (CH2), 33.4 (CH2), 41.3 (CH2), 59.2 (CH), 111.3 (C), 122.3 (CH), 125.5 (CH), 127.4 (CH), 128.0 (CH), 129.4 (CH), 130.8 (CH), 132.7 (CH), 133.7 (C), 134.1 (C), 134.2 (C), 135.7 (C), 150.5 (C), 170.1 (C), 177.3 (C); IR ν (cm-1): 3268, 3202, 3063, 1714, 1644, 1541, 1218, 748; 元素分析:C19H16BrCl2N3O3の計算値: C, 47.04; H, 3.32; N, 8.66. 実測値: C, 47.03; H, 3.30; N, 8.66%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び2-ヨードフェニルイソシアネート(0.94g、3.8mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2759を収率58%で得た(1.07g、2.0mmol)。mp 203〜207℃(MeOH);TLC Rf (CH2Cl2/MeOH:95/5) 0.7; 1H NMR (CDCl3, 400 MHz) δ ppm 2.18-2.31 (m, 1H, CH2CH2CH), 2.36-2.45 (m, 1H, CH2CH2CH), 2.59-2.68 (m, 1H, CH2CH2CH), 3.00-3.12 (m, 1H, CH2CH2CH), 4.52 (t, J = 5.8 Hz, 2H, NHCH2), 4.82 (dd, J = 8.7, 1.7 Hz, 1H, CH2CH2CH), 6.82 (s, 1H, NHCH2), 6.88 (td, J = 7.6, 1.6 Hz, 1H, ArH), 7.21 (dd, J = 8.1, 2.3 Hz, 1H, ArH), 7.30-7.39 (m, 3H, ArH), 7.84 (dd, J = 8.1, 1.5 Hz, 1H, ArH), 7.96 (dd, J = 8.3, 1.5 Hz, 1H, ArH), 10.68 (s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.3 (CH2), 32.5 (CH2), 41.3 (CH2), 59.2 (CH), 90.4 (C), 123.0 (CH), 126.4 (CH), 127.4 (CH), 128.8 (CH), 129.4 (CH), 130.8 (C), 133.8 (C), 134.1 (C), 134.2 (C), 138.5 (C), 139.5 (CH), 150.7 (C), 170.1 (C), 177.2 (C); IR ν (cm-1): 3265, 3207, 3076, 1714, 1644, 1533, 1217, 754; 元素分析:C19H16Cl2IN3O3の計算値: C, 42.88; H, 3.03; N, 7.90. 実測値: C, 42.82; H, 2.98; N, 8.04%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び2,4-ジクロロフェニルイソシアネート(0.66g、3.5mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2331を収率87%で得た(1.45g、3.1mmol)。mp 203〜218℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2) 0.6; 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.86-1.96 (m, 1H, CH2CH2CH), 2.29-2.43 (m, 1H, CH2CH2CH), 2.60-2.81 (m, 2H, CH2CH2CH), 4.36 (m, 2H, CH2CH2CH及びNHCH2), 4.81 (dd, J = 9.6, 2.8 Hz, 1H, NHCH2), 7.41 (d, J = 8.0 Hz, 1H, ArH), 7.43 (d, J = 2.0 Hz, 1H, ArH), 7.47 (dd, J = 9.2, 2.0 Hz, 1H, ArH), 7.62 (d, J = 2.0 Hz, 1H, ArH), 7.74 (d, J = 2.0 Hz, 1H, ArH), 8.24 (d, J = 9.2 Hz, 1H, ArH), 8.88 (t, J = 2.0 Hz, 1H, NHCH2), 11.11 (br s, 1H, NHAr); 13C NMR (DMSO-d6, 100 MHz) δ ppm 21.5 (CH2), 31.7 (CH2), 39.5 (CH2), 58.7 (CH), 121.9 (CH), 123.0 (CH), 127.3 (CH), 127.7 (C), 128.1 (CH), 128.6 (CH), 128.8 (CH), 130.1 (C), 132.3 (C), 133.0 (C), 133.6 (C), 135.2 (C), 149.3 (C), 171.0 (C), 178.2 (C); LC-MS (APCI+) m/z: 475.9 (MH+), tr 4.78分; IR ν (cm-1): 3263, 1716, 1656, 1582, 1537, 1224, 823; 元素分析:C19H15Cl4N3O3の計算値: C, 48.03; H, 3.18; N, 8.84. 実測値: C, 48.02; H, 3.17; N, 8.76%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び2,4-ジメトキシフェニルイソシアネート(0.62g、3.5mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2333を収率83%で得た(1.35g、2.9mmol)。mp 203〜205℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2) 0.6; 1H NMR (CDCl3, 400 MHz) δ ppm 2.15-2.23 (m, 1H, CH2CH2CH), 2.35-2.43 (m, 1H, CH2CH2CH), 2.55-2.63 (m, 1H, CH2CH2CH), 2.92-3.05 (m, 1H, CH2CH2CH), 3.80 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.45 (dd, J = 15.2, 6.0 Hz, 1H, NHCH2), 4.54 (dd, J = 15.2, 6.0 Hz, 1H, NHCH2), 4.84 (dd, J = 8.8, 1.6 Hz, 1H, CH2CH2CH), 6.44 (dd, J = 8.8, 2.8 Hz, 1H, ArH), 6.50 (d, J = 2.8 Hz, 1H, ArH), 7.10 (t, J = 6.0 Hz, 1H, NHCH2), 7.17 (dd, J = 8.0, 2.0 Hz, 1H, ArH), 7.31 (d, J = 8.0 Hz, 1H, ArH), 7.34 (d, J = 2.0 Hz, 1H, ArH), 7.93 (d, J = 8.8 Hz, 1H, ArH), 10.71 (br s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.4 (CH2), 32.7 (CH2), 41.3 (CH2), 55.7 (CH), 56.0 (CH3), 59.2 (CH3), 98.9 (CH), 103.9 (CH), 120.3 (CH), 121.1 (CH), 127.5 (CH), 129.5 (C), 130.7 (CH), 134.0 (C), 134.1 (C), 134.2 (C), 150.4 (C), 150.5 (C), 157.0 (C), 170.5 (C), 177.2 (C); LC-MS (APCI+) m/z: 466.0 (MH+), tr 4.33分; IR ν (cm-1): 3294, 1712, 1657, 1547, 1299, 1205, 1033, 818; 元素分析:C21H21Cl2N3O5の計算値: C, 54.09; H, 4.54; N, 9.01. 実測値: C, 53.91; H, 3.81; N, 8.91%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(0.70g、2.4mmol)、及び2,4,6-トリメチルフェニルイソシアネート(0.39g、2.4mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2338を収率55%で得た(0.60g、1.3mmol)。mp 156〜157℃(MeOH);TLC Rf (CH2Cl2/MeOH:95/5) 0.8; 1H NMR (CDCl3, 400 MHz) δ ppm 2.14 (s, 6H, CCH3), 2.18-2.24 (m, 1H, CH2CH2CH), 2.27 (s, 3H, CCH3), 2.38-2.45 (m, 1H, CH2CH2CH), 2.55-2.65 (m, 1H, CH2CH2CH), 2.98-3.10 (m, 1H, CH2CH2CH), 4.42 (dd, J = 6.0, 2.0 Hz, 2H, NHCH2), 4.83 (dd, J = 8.4, 1.6 Hz, 1H, CH2CH2CH), 6.89 (s, 2H, ArH), 7.09-7.15 (m, 2H, NHCH2及びArH), 7.23 (d, J = 8.8 Hz, 1H, ArH), 7.34 (d, J = 2.4 Hz, 1H, ArH), 9.74 (br s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 18.4 (2 CH3), 21.1 (CH3), 21.3 (CH2), 32.7 (CH2), 41.1 (CH2), 59.2 (CH), 127.4 (CH), 129.1 (2 CH), 129.4 (C), 130.4 (C), 130.5 (CH), 134.0 (CH), 134.1 (C), 134.2 (C), 135.1 (2 C), 137.3 (C), 151.7 (C), 170.5 (C), 177.8 (C); LC-MS (APCI+) m/z: 448.1 (MH+), tr 4.57分; IR ν (cm-1): 3275, 1714, 1658, 1514, 1358, 1242, 1219, 1033, 826; 元素分析:C22H23Cl2N3O3の計算値: C, 58.94; H, 5.17; N, 9.37. 実測値: C, 58.80; H, 5.26; N, 9.25%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び3-トリフルオロメチルフェニルイソシアネート(0.65g、3.5mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2337を収率73%で得た(1.20g、2.5mmol)。mp 171〜174℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2) 0.6; 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.90-1.98 (m, 1H, CH2CH2CH), 2.30-2.42 (m, 1H, CH2CH2CH), 2.60-2.80 (m, 2H, CH2CH2CH), 4.35-4.39 (m, 2H, CH2CH2CH及びNHCH2), 4.81 (dd, J = 9.6, 2.8 Hz, 1H, NHCH2), 7.38 (dd, J = 8.8, 2.4 Hz, 1H, ArH), 7.45 (d, J = 8.4 Hz, 1H, ArH), 7.47 (d, J = 8.4 Hz, 1H, ArH), 7.59 (t, J = 8.4 Hz, 1H, ArH), 7.61 (d, J = 2.4 Hz, 1H, ArH), 7.72 (d, J = 8.8 Hz, 1H, ArH), 8.07 (s, 1H, ArH), 8.88 (t, J = 6.0 Hz, 1H, NHCH2), 10.68 (br s, 1H, NHAr); 13C NMR (DMSO-d6, 100 MHz) δ ppm 21.8 (CH2), 32.2 (CH2), 40.6 (CH2), 59.2 (CH), 116.3 (q, J = 3.8 Hz, CH), 127.0 (m, CH), 124.0 (CH), 124.3 (q, J = 272.0 Hz, CF3), 127.6 (CH), 129.0 (CH), 130.0 (q, J = 32 Hz, C), 130.2 (CH), 130.6 (CH), 132.8 (C), 133.4 (C), 135.7 (C), 138.6 (C), 150.1 (C), 171.5 (C), 178.2 (C); 19F NMR (CDCl3, 376 MHz) δ ppm -61.4 (CF3); LC-MS (APCI+) m/z: 474.0 (MH+), tr 4.58分; IR ν (cm-1): 3298, 1727, 1658, 1556, 1450, 1333, 1251, 1112, 831; 元素分析:C20H16Cl2F3N3O3の計算値: C, 50.65; H, 3.40; N, 8.86. 実測値: C, 50.34; H, 3.30; N, 8.74%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.50g、5.2mmol)及び3,4-ジクロロフェニルイソシアネート(0.98g、5.2mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2328を収率81%で得た(2.00g、4.2mmol)。mp 220〜224℃(MeOH);TLC Rf (CH2Cl2/MeOH:98/2) 0.7; 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.84-1.97 (m, 1H, CH2CH2CH), 2.25-2.40 (m, 1H, CH2CH2CH), 2.60-2.80 (m, 2H, CH2CH2CH), 4.36 (s, 2H, NHCH2), 4.79 (d, J = 8.5 Hz, 1H, CH2CH2CH), 7.38-7.65 (m, 5H, NHCH2及びArH), 7.94 (s, 1H, ArH), 8.86 (s, 1H, ArH), 10.59 (br s, 1H, NHAr); 13C NMR (DMSO-d6, 100 MHz) δ ppm 21.5 (CH2), 31.7 (CH2), 39.5 (CH2), 58.7 (CH), 120.0 (CH), 121.1 (CH), 125.4 (C), 127.3 (CH), 128.6 (CH), 130.2 (CH), 130.8 (CH), 131.2 (C), 132.3 (C), 133.0 (C), 135.2 (C), 137.5 (C), 149.4 (C), 171.0 (C), 177.7 (C); LC-MS (APCI+) m/z: 474.0 (MH+), tr 4.67分; IR ν (cm-1): 3270, 1718, 1644, 1598, 1547, 1476, 1218, 1134, 818; 元素分析:C19H15Cl4N3O3の計算値: C, 48.03; H, 3.18; N, 8.84. 実測値: C, 47.75; H, 3.03; N, 8.71%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び3,5-ビス(トリフルオロメチル)フェニルイソシアネート(0.89g、3.5mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2336を収率64%で得た(1.20g、2.2mmol)。TLC Rf (CH2Cl2/MeOH:98/2) 0.6;mp 223〜225℃(MeOH); 1H NMR (CDCl3, 400 MHz) δ ppm 2.23-2.36 (m, 2H, CH2CH2CH), 2.60-2.70 (m, 1H, CH2CH2CH), 2.98-3.12 (m, 1H, CH2CH2CH), 4.49 (dd, J = 15.2, 5.6 Hz, 1H, NHCH2), 4.57 (dd, J = 15.2, 5.6 Hz, 1H, NHCH2), 4.78 (dd, J = 7.2, 2.8 Hz, 1H, CH2CH2CH), 6.66 (t, J = 5.6 Hz, 1H, NHCH2), 7.20 (dd, J = 8.4, 2.4 Hz, 1H, ArH), 7.34 (d, J = 8.4 Hz, 1H, ArH), 7.36 (d, J = 2.4 Hz, 1H, ArH), 7.62 (s, 1H, ArH), 7.99 (s, 2H, ArH), 10.91 (br s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.4 (CH2), 32.4 (CH2), 41.4 (CH2), 59.2 (CH), 117.7 (q, J = 3.9 Hz, CH), 119.8 (m, 2CH), 123.0 (q, J = 272.0 Hz, 2 CF3), 127.5 (CH), 129.5 (CH), 130.9 (CH), 132.4 (q, J = 32.0 Hz, 2C), 133.5 (C), 134.2 (C), 134.4 (C), 138.6 (C), 150.2 (C), 170.0 (C), 177.8 (C); 19F NMR (CDCl3, 100 MHz) δ ppm -63.1 (CF3); LC-MS (APCI+) m/z: 543.8 (MH+), tr 5.05分; IR ν (cm-1): 3290, 3089, 1725, 1656, 1561, 1284, 1172, 1128, 1042, 890; 元素分析:C21H15Cl2F6N3O3の計算値: C, 46.51; H, 2.79; N, 7.75. 実測値: C, 46.49; H, 2.61; N, 7.69%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び4-クロロフェニルイソシアネート(0.54g、3.5mmol)を使用して一般手順に従った。所望の生成物をシリカカラム(CH2Cl2/MeOH 1/0〜99/1)で精製して、純粋なHEI_2278を白色固体として収率68%で得た(1.05g、2.4mmol)。mp 188〜191℃(CH2Cl2/MeOH);TLC Rf (EtOAc/n-ヘプタン:4/6) 0.3; 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.85-1.95 (m, 1H, CH2CH2CH), 2.30-2.40 (m, 1H, CH2CH2CH), 2.58-2.78 (m, 2H, CH2CH2CH), 4.35 (m, 2H, CH2CH2CH及びNHCH2), 4.79 (dd, J = 9.2, 6.0 Hz, 1H, NHCH2), 7.40 (d, J = 8.8 Hz, 2H, ArH), 7.42 (m, 2H, ArH), 7.57 (d, J = 8.8 Hz, 2H, ArH), 7.62 (d, J = 1.5 Hz, 1H, ArH), 8.85 (t, J = 6.0 Hz, 1H, NHCH2), 10.54 (br s, 1H, NHAr); 13C NMR (DMSO-d6, 100 MHz) δ ppm 21.4 (CH2), 31.8 (CH2), 38.3 (CH2), 58.7 (CH), 121.2 (2 CH), 127.3 (CH), 127.5 (C), 128.6 (CH), 128.9 (2 CH), 130.1 (CH), 132.3 (C), 132.9 (C), 135.2 (C), 136.3 (C), 149.4 (C), 171.1 (C), 177.8 (C); LC-MS (APCI+) m/z: 439.9 (MH+), tr 4.50分; IR ν (cm-1): 3283, 2922, 1712, 1649, 1600, 1545, 1388, 1224, 1051, 828; 元素分析:C19H16Cl3N3O3の計算値: C, 51.78; H, 3.66; N, 9.53. 実測値: C, 52.02; H, 3.92; N, 9.38%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び2,4-ジクロロベンジルイソシアネート(0.77g、3.8mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2817を収率78%で得た(1.31g、2.7mmol)。TLC Rf (CH2Cl2/MeOH:95/5) 0.7;mp 224〜226℃(MeOH); 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.81-1.91 (m, 1H, CH2CH2CH), 2.24-2.37 (m, 1H, CH2CH2CH), 2.43-2.72 (m, 2H, CH2CH2CH), 4.31 (d, J = 5.7 Hz, 2H, NCH2), 4.44 (d, J = 5.7 Hz, 2H, NCH2), 4.69 (dd, J = 9.2, 2.6 Hz, 1H, CH2CH2CH), 7.24-7.43 (m, 4H, ArH), 7.61 (dd, J = 7.4, 2.0 Hz, 2H, ArH), 8.77 (t, J = 6.3 Hz, 1H, NH), 8.86 (t, J = 6.3 Hz, 1H, NH); 13C NMR (DMSO-d6, 100 MHz) δ ppm 22.0 (CH2), 32.1 (CH2), 40.6 (CH2), 40.9 (CH2), 59.0 (CH), 127.6 (CH), 127.7 (CH), 128.9 (CH), 129.0 (CH), 130.4 (CH), 130.6 (CH), 132.6 (CH), 132.8 (CH), 133.2 (C), 133.3 (C), 135.7 (C), 135.8 (C), 152.5 (C), 171.8 (C), 177.6 (C); IR ν (cm-1): 3251, 3089, 1709, 1653, 1538, 1239; 元素分析:C20H17Cl4N3O3の計算値: C, 49.11; H, 3.50; N, 8.59. 実測値: C, 49.12; H, 3.50; N, 8.60%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.5mmol)及び3,4-ジクロロベンジルイソシアネート(0.67g、3.3mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2820を収率32%で得た(0.54g、1.1mmol)。mp 201〜204℃(MeOH);TLC Rf (CH2Cl2/MeOH:95/5) 0.7; 1H NMR (CDCl3, 400 MHz) δ ppm 2.12-2.25 (m, 1H, CH2CH2CH), 2.31-2.41 (m, 1H, CH2CH2CH), 2.49-2.59 (m, 1H, CH2CH2CH), 2.89-3.01 (m, 1H, CH2CH2CH), 4.33-4.57 (m, 4H, NCONHCH2, CHCONHCH2, CH2CH2CH), 4.74 (d, J = 9.3 Hz, 1H, CHCONHCH2), 6.86 (s, 1H, CHCONHCH2), 7.11 (d, J = 9.3 Hz, 1H, ArH), 7.16-7.22 (m, 1H, ArH), 7.27-7.34 (m, 1H, ArH), 7.36-7.42 (m, 3H, ArH), 8.88 (s, 1H, NCONHCH2); 13C NMR (CDCl3, 100 MHz) δ ppm 21.3 (CH2), 32.4 (CH2), 41.2 (CH2), 42.8 (CH2), 59.1 (CH), 126.8 (CH), 127.4 (CH), 129.3 (CH), 129.4 (CH), 130.6 (CH), 130.7 (CH), 132.8 (C), 133.7 (C), 134.1 (C), 134.1 (C), 138.2 (C), 153.3 (C), 170.2 (C), 177.4 (C), 184.0 (C); IR ν (cm-1): 3320, 3274, 3058, 2943, 1707, 1650, 1542, 1243, 816; 元素分析:C20H17Cl4N3O3の計算値: C, 49.11; H, 3.50; N, 8.59. 実測値: C, 49.14; H, 3.58; N, 8.53%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソ-ピロリジン-2-カルボキサミド(0.83g、2.9mmol)及びチオフェン-2-イルイソシアネート(0.40g、3.2mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2548を収率26%で得た(0.31g、0.8mmol)。mp 141〜143℃(MeOH);TLC Rf (CH2Cl2/MeOH:99/1) 0.5; 1H NMR (CDCl3, 400 MHz) δ ppm 2.20-2.31 (m, 1H, CH2CH2CH), 2.35-2.41 (m, 1H, CH2CH2CH), 2.62 (td, J = 18.1, 9.4 Hz, 1H, CH2CH2CH), 3.06 (td, J = 17.6, 9.4 Hz, 1H, CH2CH2CH), 4.50-4.55 (m, 2H, NHCH2), 4.85 (dd, J = 9.0, 1.6 Hz, 1H, CH2CH2CH), 6.73 (dd, J = 3.9, 1.5 Hz, 1H, ArH), 6.89 (dd, J = 5.5, 3.5 Hz, 1H, ArH), 6.92 (dd, J = 5.5, 1.5 Hz, 1H, ArH), 6.95 (br t, J = 4.6 Hz, 1H, NHCH2), 7.21 (dd, J = 8.2, 2.0 Hz, 1H, ArH), 7.34 (d, J = 8.3 Hz, 1H, ArH), 7.37 (d, J = 1.9 Hz, 1H, ArH), 11.00 (s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.6 (CH2), 32.2 (CH2), 41.2 (CH2), 59.1 (CH), 113.4 (CH), 118.4 (CH), 124.5 (CH), 127.3 (CH), 129.3 (CH), 130.6 (CH), 133.6 (C), 134.0 (C), 134.1 (C), 137.9 (C), 149.6 (C), 170.2 (C), 177.5 (C); IR ν (cm-1): 3291, 1712, 1660, 1556, 1510, 1343, 1245, 1218, 815, 689; 元素分析:C17H15Cl2N3O3Sの計算値: C, 49.52; H, 3.67; N, 10.19; S, 7.78. 実測値: C, 49.23; H, 3.80; N, 10.00; S, 7.03%.
(S)-N-(2,4-ジクロロベンジル)-5-オキソピロリジン-2-カルボキサミド(1.86g、6.5mmol)及び6-クロロピリジン-3-イルイソシアネート(1.00g、6.5mmol)を使用して一般手順に従った。所望の生成物をシリカカラム(CH2Cl2/MeOH 1/0〜9/1)で精製して、純粋なHEI_3090を白色固体として収率11%で得た(0.30g、0.7mmol)。mp 187〜190℃(CH2Cl2/MeOH);TLC Rf (CH2Cl2/MeOH:95/5) 0.8; 1H NMR (CDCl3, 400 MHz) δ ppm 2.12-2.37 (m, 2H, CH2CH2CH), 2.59-2.68 (m, 1H, CH2CH2CH), 2.99-3.10 (m, 1H, CH2CH2CH), 4.49 (dd, J = 15.2, 6.2 Hz, 1H, NHCH2), 4.55 (dd, J = 15.2, 6.2 Hz, 1H, NHCH2), 4.77 (dd, J = 8.7, 2.1 Hz, 1H, CH2CH2CH), 6.65 (br t, J = 6.2 Hz, 1H, NHCH2), 7.22 (dd, J = 8.1, 2.0 Hz, 1H, ArH), 7.29 (d, J = 8.6 Hz, 1H, ArH), 7.33 (d, J = 8.1 Hz, 1H, ArH), 7.38 (d, J = 2.0 Hz, 1H, ArH), 7.92 (dd, J = 8.6, 2.5 Hz, 1H, ArH), 8.49 (d, J = 2.5 Hz, 1H, ArH), 10.66 (s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.4 (CH2), 32.4 (CH2), 41.4 (CH2), 59.2 (CH), 124.3 (CH), 127.5 (CH), 129.5 (CH), 130.2 (CH), 130.9 (CH), 133.1 (C), 133.6 (2 C), 134.2 (C), 141.3 (CH), 146.2 (C), 150.3 (C), 170.0 (C), 177.7 (C); IR ν (cm-1): 3271, 3095, 2935, 1721, 1655, 1594, 1542, 1464, 1217, 1104.
(S)-N-[2-(2,4-ジクロロフェニル)エチル]-5-オキソ-ピロリジン-2-カルボキサミド(1.00g、3.3mmol)及び3,4-ジクロロフェニルイソシアネート(0.69g、3.7mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_2773を収率51%で得た(0.80g、1.6mmol)。mp 213〜216℃(MeOH);TLC Rf (CH2Cl2/MeOH:95/5) 0.7; 1H NMR (DMSO-d6, 400 MHz) δ ppm 1.70-1.85 (m, 1H, CH2CH2CH), 2.19-2.36 (m, 1H, CH2CH2CH), 2.57-2.71 (m, 2H, CH2CH2CH), 2.78-2.92 (m, 2H, CH2CH2Ar), 3.25-3.46 (m, 2H, CH2CH2Ar), 4.63 (dd, J = 9.5, 2.9 Hz, 1H, CH2CH2CH), 7.30-7.38 (m, 2H, ArH), 7.49 (dd, J = 8.6, 2.4 Hz, 1H, ArH), 7.54-7.65 (m, 2H, ArH), 7.94 (d, J = 2.5 Hz, 1H, ArH), 8.36 (s, 1H, NH), 10.60 (s, 1H, NH); 13C NMR (DMSO-d6, 100 MHz) δ ppm 22.1 (CH2), 32.1 (CH2), 32.6 (CH2), 38.5 (CH2), 59.1 (CH), 120.3 (CH), 121.4 (CH), 125.8 (C), 127.6 (CH), 129.0 (CH), 131.2 (CH), 131.6 (C), 132.2 (C), 133.0 (CH), 134.5 (C), 136.2 (C), 137.9 (C), 149.7 (C), 171.0 (C), 178.2 (C); IR ν (cm-1): 3267, 3105, 1716, 1652, 1592, 1542, 1220, 807; 元素分析:C20H17Cl4N3O3の計算値: C, 49.11; H, 3.50; N, 8.59. 実測値: C, 48.99; H, 3.37; N, 8.50%.
N-(2,4-ジクロロベンジル)-5-オキソピロリジン-3-カルボキサミド(0.83g、2.9mmol)及び4-クロロピリジン-3-イルイソシアネート(0.40g、3.2mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_3127を収率26%で得た(0.31g、0.8mmol)。TLC Rf (CH2Cl2/MeOH:99/1)=0.5;mp (EtOH)=141〜143℃; 1H NMR (CDCl3, 400 MHz) δ ppm 2.20-2.31 (m, 1H, CH2CH2CH), 2.35-2.41 (m, 1H, CH2CH2CH), 2.62 (td, J = 18.1, 9.4 Hz, 1H, CH2CH2CH), 3.06 (td, J = 17.6, 9.4 Hz, 1H, CH2CH2CH), 4.50-4.55 (m, 2H, NHCH2), 4.85 (dd, J = 9.0, 1.6 Hz, 1H, CH2CH2CH), 6.73 (dd, J = 3.9, 1.5 Hz, 1H, ArH), 6.89 (dd, J = 5.5, 3.5 Hz, 1H, ArH), 6.92 (dd, J = 5.5, 1.5 Hz, 1H, ArH), 6.95 (br t, J = 4.6 Hz, 1H, NHCH2), 7.21 (dd, J = 8.2, 2.0 Hz, 1H, ArH), 7.34 (d, J = 8.3 Hz, 1H, ArH), 7.37 (d, J = 1.9 Hz, 1H, ArH), 11.00 (s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.6 (CH2), 32.2 (CH2), 41.2 (CH2), 59.1 (CH), 113.4 (CH), 118.4 (CH), 124.5 (CH), 127.3 (CH), 129.3 (CH), 130.6 (CH), 133.6 (C), 134.0 (C), 134.1 (C), 137.9 (C), 149.6 (C), 170.2 (C), 177.5 (C); IR ν (cm-1): 3291, 1712, 1660, 1556, 1510, 1343, 1245, 1218, 815, 689; 元素分析:C17H15Cl2N3O3Sの計算値: C, 49.52; H, 3.67; N, 10.19; S, 7.78. 実測値: C, 49.23; H, 3.80; N, 10.00; S, 7.03%.
N-(2,4-ジクロロベンジル)-5-オキソピロリジン-3-カルボキサミド(0.83g、2.9mmol)及び3,4-ジクロロフェニルイソシアネート(0.40g、3.2mmol)を使用して一般手順に従った。所望の生成物が、MeOH中、白色粉末として結晶化し、これをろ過して、純粋なHEI_3204を収率26%で得た(0.31g、0.8mmol)。TLC Rf (CH2Cl2/MeOH:99/1)=0.5;mp (EtOH)=141〜143℃; 1H NMR (CDCl3, 400 MHz) δ ppm 2.20-2.31 (m, 1H, CH2CH2CH), 2.35-2.41 (m, 1H, CH2CH2CH), 2.62 (td, J = 18.1, 9.4 Hz, 1H, CH2CH2CH), 3.06 (td, J = 17.6, 9.4 Hz, 1H, CH2CH2CH), 4.50-4.55 (m, 2H, NHCH2), 4.85 (dd, J = 9.0, 1.6 Hz, 1H, CH2CH2CH), 6.73 (dd, J = 3.9, 1.5 Hz, 1H, ArH), 6.89 (dd, J = 5.5, 3.5 Hz, 1H, ArH), 6.92 (dd, J = 5.5, 1.5 Hz, 1H, ArH), 6.95 (br t, J = 4.6 Hz, 1H, NHCH2), 7.21 (dd, J = 8.2, 2.0 Hz, 1H, ArH), 7.34 (d, J = 8.3 Hz, 1H, ArH), 7.37 (d, J = 1.9 Hz, 1H, ArH), 11.00 (s, 1H, NHAr); 13C NMR (CDCl3, 100 MHz) δ ppm 21.6 (CH2), 32.2 (CH2), 41.2 (CH2), 59.1 (CH), 113.4 (CH), 118.4 (CH), 124.5 (CH), 127.3 (CH), 129.3 (CH), 130.6 (CH), 133.6 (C), 134.0 (C), 134.1 (C), 137.9 (C), 149.6 (C), 170.2 (C), 177.5 (C); IR ν (cm-1): 3291, 1712, 1660, 1556, 1510, 1343, 1245, 1218, 815, 689; 元素分析:C17H15Cl2N3O3Sの計算値: C, 49.52; H, 3.67; N, 10.19; S, 7.78. 実測値: C, 49.23; H, 3.80; N, 10.00; S, 7.03%.
本発明の化合物の生物学的適用
統計解析
結果を平均±SEMとして表す。統計解析にはPrism 6ソフトウェア(GraphPad社)を用いた。2つの群間差の重要性を評価するためにマン-ホイットニー検定(*、p<0.05;**、p<0.01;***、p<0.001;****、p<0.0001)を用いた。発生曲線をMantel-Cox(ログランク)検定で分析した。
HEI 2333及びHEI 2336の毒性は、60個の腫瘍細胞株のNCIパネル(NCI 60-細胞パネル)において既に試験していた。
P2X受容体のうちのいずれも一切発現しないHEK細胞(模擬)を、mP2rx7遺伝子についてコードしている発現ベクターでトランスフェクトした。カチオンチャネル活性を、Fluo4 AM(インビトロゲン)プローブ、及びTopro3(インビトロゲン)を有する大きい開孔でアッセイした。各実験において、2×106個の細胞を50nM Fluo4-AMで30分間インキュベートした。洗浄後、50μMでの本発明の化合物の存在下で、細胞を500μMのBzATP(3'-O-(4-ベンゾイル)ベンゾイルATP)で1時間処置し、又は処置しなかった。示されているとき、1時間の刺激時間の間にTopro3プローブ(8.5nM)を添加した。蛍光をフローサイトメトリーによりアッセイした。
安定性を、マウス肝ミクロソーム系(図13A)及びヒトにおいて(図示せず)、HEI3090分子についてin vivoで直接、研究した(図13B)。これらの実験は、HEI3090を注射した(腹腔内、10%DMSO中1.5mg/kg)マウスの血漿において、最大2.5μMの濃度でHEI3090が見出されることを強調した。
・臨床的スコア
P2RX7が、結腸の慢性炎症性疾患であるクローン疾患患者における炎症性応答をモジュレートすることが過去に明示されており(Cesaro Aら、Amplification loop of the inflammatory process is induced by P2X7R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. Am J Physiol Gastrointest Liver Physiol、2010. 299(1):G32〜42頁)、発明者らは、DSS誘起の大腸炎マウスモデルにおいてHEI2328の効果を試験した。
体重減少を以下の通りスコア付けした:0、減少なし;1、減少<5%;2、減少<10%;3、減少<20%、及び4、減少>20%。
排泄物の粘稠度のスコアを以下の通り測定した:0、正常;1、ゆるい排泄物;2、水様性下痢;又は3、重度の水様性下痢。
直腸出血を以下の通りスコア付けした:0、出血なし;1、点状出血の存在;2、微量の出血を伴う排泄物;又は3、出血。
第15日に、マウスを安楽死させ、直腸から盲腸までの結腸部分を取り出し、測定し、結腸の1/3下部を写実した横断断面、1/3下部から直腸までを写実した縦断断面において、組織学的スコアを確立した。炎症スコアを、訓練を受けたの病理学者が実施した。簡潔に言うと、炎症の重篤度(なし、軽度、中等度、重度)、炎症の程度(なし、粘膜、粘膜下及び壁内)、陰窩損傷(なし、基底〜1/3、基底〜2/3、陰窩欠損、陰窩及び上皮欠損)、並びに炎症により影響を受けた組織の百分率(0、25、50、75及び100%)をスコア付けした。
HEI2328がマウスにおけるDSS誘起の大腸炎を強力に阻害するという観察は、反直感的である。実際に、BzATPを増強して大きい開孔を増加させることによって、IL1Bの生成の増加、及び結果として大腸炎の悪化を予測することができた。P2RX7は免疫細胞によって発現されるので、発明者らは、処置マウス対非処置マウスの脾臓内の各免疫細胞集団の割合を特徴づけることを考えた。図5Aに示す通り、発明者らは、HEI2328で処置したマウスにおける、リンパ球集団(76%に対して67%)について好ましい骨髄浸潤の有意な低下(17%に対して28%)を観察した。リンパ球集団内で、TregとTγδリンパ球との両方が増加している(図5B)。骨髄浸潤内で、HEI2328は炎症性単球(CD11b+CD11c-Ly6c+Ly6g-CD3-NK1.1-B220-)の割合を統計的に減少させた。対照的に、HEI2328での処置は、従来のDC(cDC)と形質細胞様DC(pDC)との両方の割合を変更しなかった(図5C、図5D)。
4.1.処置マウスの脾臓においてHEI2328がM-MDSC(骨髄由来サプレッサー細胞)の割合に影響を与えたことを明示しており、発明者らは、HEI2328が免疫抑制を低減し、したがって抗腫瘍応答を強化しうるという仮説を設けた。この仮説を試験すべく、免疫担当性C57BI6J(Envigo、Gannat France社)マウスに黒色腫細胞株B16-F10を注射した。第1に、発明者らは、B16F10細胞がHEI2328処置に感応性であることをin vitroで明示した。図6に示す通り、BzATPで処置した細胞にHEI2328を添加すると、大きい開孔は6倍超増加し、これは、Topro3陽性細胞の数の増加により例示される。興味深いことに、発明者らは、BzATPの不在下で、HEI2328単独は毒性作用を有していないことを認めた。
- HEI3090は、ATP豊富な微小環境中でP2RX7を増強する第1の分子である。
- HEI3090は、内因性P2RX7のリガンド(ATP)の不在下で非毒性であり、これは、炎症性及び/又は腫瘍の微小環境中でのみ見出される。これを、hP2PX7又はmP2RX7で安定にトランスフェクトしたHEK細胞株において、及び60個のヒト腫瘍細胞株のNCIパネルにおいて試験した。
- HEI3090は、P2RX7に特異的であり、これは、P2rx7-/-マウスから調製した脾細胞において試験したときの、効果の不在により明示される。
- HEI3090は、P2RX7の正のアロステリックモジュレーターであり、ATP及び3'-O-(4-ベンゾイル)ベンゾイルATP(BzATP)についてEC50を低下させ、P2RX7発現細胞の、ATP誘起の細胞死を増加させる。
- HEI3090は、同系マウス腫瘍モデルにおける肺(ルイス肺癌)及び黒色腫(B16-F10)の腫瘍増殖をブロックし、これは、療法的に処置したマウスにおける第22日から第50日のマウス全生存期間の増加によって証明される。
- HEI3090抗腫瘍効果は、部分的に、T CD4+リンパ球によって媒介される。
- HEI3090は、IL18細胞及びNK細胞により媒介される抗腫瘍応答をトリガーし、これは、IL18が枯渇しているマウス(抗体マウス及びIl18-/-マウスをブロックする)及びNK細胞(抗NK1.1抗体)が枯渇しているマウスにおける、化合物の効果の欠如により証明される。
- HEI3090は、腫瘍免疫原性を増加させ、これは、MHC-I及びPD-L1について陽性である腫瘍細胞の数の増加により証明される。
- HEI3090は、抗PD-1治療と併用したときに、LLC腫瘍保持マウスを治癒させる。
- HEI3090は、メモリーT細胞応答を誘起する。
Claims (16)
- 式(I):
R1は、C1〜C14アルキル、シクロアルキル基、アリール基、アラルキル基又はヘテロアリール基を表し、ここで、前記アリール基、アラルキル基又はヘテロアリール基は、非置換であり、又は
- ハロゲン原子、
- C1〜C6アルコキシ基、
- C1〜C6アルキル基、及び
- C1〜C6ハロゲノアルキル基、
から選ばれる少なくとも1つの基で置換されており、
R2は、アリール基、アラルキル基又はシクロアルキル基を表し、ここで、前記アリール基又は前記アラルキル基は、非置換であり、又はハロゲン原子から選ばれる少なくとも1つの基で置換されており、
ここで、前記化合物は、化合物:
ここで、前記化合物は、R1及びR2がそれぞれ同時に、以下のヘテロアリール基:
の化合物、それらの鏡像異性体及び医薬として許容されるそれらの塩から選ばれる化合物。 - 鏡像異性体(S)である、請求項1に記載の化合物。
- 前記シクロアルキルが、1〜12個の炭素原子を含む環状飽和炭化水素基であり、好ましくはシクロヘキシルメチル、アダマンチル及びシクロヘキシルから選ばれる、請求項1又は2に記載の化合物。
- 前記アリールが、少なくとも1個のハロゲン原子、1つのC1〜C6アルコキシ基、及び/又は1つのC1〜C6ハロゲノアルキル基により任意選択で置換されていてもよく、好ましくは2-クロロフェニル、4-クロロフェニル、2-ブロモフェニル、2-ヨードフェニル、2,4-ジクロロフェニル、3,4-ジクロロフェニル、2,4-ジメトキシフェニル、3-トリフルオロメチルフェニル、3,5-ビス(トリフルオロメチル)フェニル及び2,4,6-トリメチルフェニルから選ばれる、単環式又は多環式の芳香族炭化水素基である、請求項1から3のいずれか一項に記載の化合物。
- 前記アラルキルが、非置換であり、又は少なくとも1個のハロゲン原子、1つのC1〜C6アルコキシ基、1つのC1〜C6アルキル基又は1つのC1〜C6ハロゲノアルキル基により置換されており、好ましくはベンジル、2-クロロベンジル、2,4-ジクロロベンジル、3,4-ジクロロベンジル及び2,4-ジクロロフェネチルから選ばれる、請求項1から4のいずれか一項に記載の化合物。
- 前記ヘテロアリールが、芳香環の少なくとも1個の炭素原子がヘテロ原子、好ましくは窒素により置換されているアリール基であり、好ましくは前記ヘテロアリールが、非置換であってもよく、又は少なくとも1個のハロゲン原子、1つのC1〜C6アルコキシ基、及び/若しくは1つのC1〜C6ハロゲノアルキル基により置換されていてもよく、より好ましくは前記ヘテロアリールが、6-クロロピリジン-3-イル又はチオフェン-2-イルである、請求項1から5のいずれか一項に記載の化合物。
- 医薬としての使用のための、請求項1から8のいずれか一項に記載の化合物。
- 炎症性疾患及び/又はがんを予防する及び/又は治療するための使用のための、請求項1から8のいずれか一項に記載の化合物。
- 前記炎症性疾患が、関節リウマチ、クローン病、炎症性腸疾患、変形性関節症及び骨粗鬆症から好ましくは選ばれる慢性炎症性疾患であり;及び/又は、前記がんが、結腸がん、結腸直腸がん、黒色腫、乳がん、甲状腺がん、前立腺がん、卵巣がん、肺がん、膵がん、グリオーマ、子宮頸がん、子宮内膜がん、頭頚部がん、肝がん、腎がん、皮膚がん、胃がん、精巣がん、尿路上皮がん若しくは副腎皮質癌から選択されるが、リンパ腫等の非固形がんからも選択される、請求項10に記載の使用のための化合物。
- a)請求項1から8のいずれか一項に記載の少なくとも1種の化合物と、
b)少なくとも1種の付加的な療法と
を含む、がんの治療及び/又は予防における、同時の、別々の又は順次の使用のための併用製品としての製品。 - 前記付加的な療法b)が、抗チェックポイント抗体から選ばれ、好ましくは抗PD1抗体から選ばれ、より好ましくはニボルマブ及びペンブロリズマブから選ばれ、及び/又は前記がんが、肺がん、好ましくはルイス肺がんである、請求項12に記載の製品。
- 前記化合物が、P2RX7モジュレーターである、請求項9から13のいずれか一項に記載の使用のための、化合物。
- 医薬として許容される担体中に、請求項1から8のいずれか一項に記載の少なくとも1種の化合物を含む、医薬組成物。
- 炎症性疾患及び/又はがんを予防する及び/又は治療するための使用のための、ATPの存在下で大きい開孔を介して細胞死を誘起することができる化合物である、P2RX7モジュレーター。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023187637A JP2023184627A (ja) | 2018-03-29 | 2023-11-01 | 療法におけるp2rx7モジュレーター |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305361 | 2018-03-29 | ||
EP18305361.0 | 2018-03-29 | ||
PCT/EP2019/058013 WO2019185868A1 (en) | 2018-03-29 | 2019-03-29 | P2rx7 modulators in therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023187637A Division JP2023184627A (ja) | 2018-03-29 | 2023-11-01 | 療法におけるp2rx7モジュレーター |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021520405A true JP2021520405A (ja) | 2021-08-19 |
Family
ID=61965876
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021501093A Pending JP2021520405A (ja) | 2018-03-29 | 2019-03-29 | 療法におけるp2rx7モジュレーター |
JP2023187637A Pending JP2023184627A (ja) | 2018-03-29 | 2023-11-01 | 療法におけるp2rx7モジュレーター |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023187637A Pending JP2023184627A (ja) | 2018-03-29 | 2023-11-01 | 療法におけるp2rx7モジュレーター |
Country Status (8)
Country | Link |
---|---|
US (1) | US11919854B2 (ja) |
EP (1) | EP3773557A1 (ja) |
JP (2) | JP2021520405A (ja) |
KR (1) | KR20210031633A (ja) |
CN (1) | CN112512520B (ja) |
CA (1) | CA3095496A1 (ja) |
IL (1) | IL277602B1 (ja) |
WO (1) | WO2019185868A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022200208A1 (en) | 2021-03-22 | 2022-09-29 | Bayer Aktiengesellschaft | Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidally active substances |
WO2022268520A1 (de) | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
CN114057720B (zh) * | 2021-12-13 | 2024-02-23 | 陶金辉 | 一种靶向p2x7r的小分子抑制剂及其在治疗结肠癌中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2273533A1 (fr) * | 1974-06-04 | 1976-01-02 | Ferlux Sa | Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5 |
JPS5466265A (en) * | 1977-10-29 | 1979-05-28 | Kyowa Hakko Kogyo Kk | Quality improving agent for citrus fruits |
JP2007501782A (ja) * | 2003-08-08 | 2007-02-01 | アストラゼネカ・アクチエボラーグ | P2x7受容体アンタゴニストとしての2−アダマンチル誘導体 |
JP2009542595A (ja) * | 2006-07-06 | 2009-12-03 | グラクソ グループ リミテッド | P2x7受容体アンタゴニストとしての置換n−フェニルメチル−5−オキソ−プロリン−2−アミドおよびそれらの使用方法 |
JP2011506554A (ja) * | 2007-12-18 | 2011-03-03 | グラクソ グループ リミテッド | P2x7調節因子としての5−オキソ−3−ピロリジンカルボキサミド誘導体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
GB0419295D0 (en) * | 2004-08-31 | 2004-09-29 | Genomica Sau | Methods and compositions to prevent neuronal degeneration |
JP2010522711A (ja) * | 2007-03-28 | 2010-07-08 | グラクソ グループ リミテッド | P2x7調節因子としてのピペリジノンカルボキサミド誘導体 |
US20100056595A1 (en) * | 2007-04-11 | 2010-03-04 | Glaxo Group Limited | Pyrazole Derivatives as P2X7 Modulators |
-
2019
- 2019-03-29 EP EP19715059.2A patent/EP3773557A1/en active Pending
- 2019-03-29 KR KR1020207028291A patent/KR20210031633A/ko active Search and Examination
- 2019-03-29 CA CA3095496A patent/CA3095496A1/en active Pending
- 2019-03-29 US US17/042,806 patent/US11919854B2/en active Active
- 2019-03-29 JP JP2021501093A patent/JP2021520405A/ja active Pending
- 2019-03-29 IL IL277602A patent/IL277602B1/en unknown
- 2019-03-29 CN CN201980024129.7A patent/CN112512520B/zh active Active
- 2019-03-29 WO PCT/EP2019/058013 patent/WO2019185868A1/en active Application Filing
-
2023
- 2023-11-01 JP JP2023187637A patent/JP2023184627A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2273533A1 (fr) * | 1974-06-04 | 1976-01-02 | Ferlux Sa | Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5 |
JPS5466265A (en) * | 1977-10-29 | 1979-05-28 | Kyowa Hakko Kogyo Kk | Quality improving agent for citrus fruits |
JP2007501782A (ja) * | 2003-08-08 | 2007-02-01 | アストラゼネカ・アクチエボラーグ | P2x7受容体アンタゴニストとしての2−アダマンチル誘導体 |
JP2009542595A (ja) * | 2006-07-06 | 2009-12-03 | グラクソ グループ リミテッド | P2x7受容体アンタゴニストとしての置換n−フェニルメチル−5−オキソ−プロリン−2−アミドおよびそれらの使用方法 |
JP2011506554A (ja) * | 2007-12-18 | 2011-03-03 | グラクソ グループ リミテッド | P2x7調節因子としての5−オキソ−3−ピロリジンカルボキサミド誘導体 |
Non-Patent Citations (3)
Title |
---|
BAUDELET, DAVY ET AL.: "Evaluation and comparison of three different separation techniques for analysis of retroamide enanti", JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, vol. 986-987, JPN6023007978, 2015, pages 35 - 43, ISSN: 0005004732 * |
HOMERIN, GERMAIN ET AL.: "ZrCl4 as a new catalyst for ester amidation: an efficient synthesis of h-P2X7R antagonists", TETRAHEDRON LETTERS, vol. 57(10), JPN6023007980, 2016, pages 1165 - 1170, ISSN: 0005004731 * |
STAMM, HELMUT ET AL.: "Reactions with aziridines. XIX. Improved synthesis of 1,3-diacyl-2-pyrrolidinones", CHEMIKER-ZEITUNG, vol. 103(4), JPN6023007979, 1979, pages 156 - 157, ISSN: 0005004730 * |
Also Published As
Publication number | Publication date |
---|---|
CA3095496A1 (en) | 2019-10-03 |
JP2023184627A (ja) | 2023-12-28 |
CN112512520B (zh) | 2023-10-24 |
CN112512520A (zh) | 2021-03-16 |
KR20210031633A (ko) | 2021-03-22 |
EP3773557A1 (en) | 2021-02-17 |
WO2019185868A1 (en) | 2019-10-03 |
US20210017131A1 (en) | 2021-01-21 |
US11919854B2 (en) | 2024-03-05 |
IL277602B1 (en) | 2024-02-01 |
IL277602A (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023184627A (ja) | 療法におけるp2rx7モジュレーター | |
JP2022534426A (ja) | Tead阻害剤およびその使用 | |
US20200061030A1 (en) | Dual inhibitors of vista and pd-1 pathways | |
US10660909B2 (en) | Method for treating cancer using chemokine antagonists | |
US11497734B2 (en) | Dual inhibitors of TIM-3 and PD-1 pathways | |
KR20210063475A (ko) | 암치료에 유용한 tie2 키나아제의 억제 방법 | |
TW202134216A (zh) | HIF-2α抑制劑 | |
JP2021530487A (ja) | Ep4阻害剤およびその合成 | |
CA3186504A1 (en) | Bicycle conjugates specific for nectin-4 and uses thereof | |
US20220211701A1 (en) | Treatment of cancer utilizing an identified adenosine fingerprint | |
JP7417804B2 (ja) | 1,2,4-オキサジアゾール化合物を用いてtigitおよびpd-1のシグナル伝達経路をモジュレートする方法 | |
JP2021522211A (ja) | Ep4阻害剤およびその使用 | |
US20190269666A1 (en) | Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer | |
JP7420402B2 (ja) | 免疫チェックポイント分子の発現抑制剤 | |
US20190083556A1 (en) | Analytical methods and arrays for use in the same | |
JP6945587B2 (ja) | ガンの処置に有用なtie2キナーゼの阻害方法 | |
TWI832069B (zh) | 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物 | |
WO2019165315A1 (en) | Method for treating cancer using chemokine antagonists alone or in combination | |
BR112023000351B1 (pt) | Uso de uma combinação compreendendo a combinação de dunniona como composto á base de naftoquinona com inibidores de checkpoint imunológico e indutores de morte celular imunogênica para o tratamento de câncer | |
EA046076B1 (ru) | Ингибиторы csf1r для применения в лечении рака | |
NZ753204B2 (en) | Dual inhibitors of vista and pd-1 pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210609 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220304 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231101 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231109 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240126 |